<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40388088</PMID><DateCompleted><Year>2025</Year><Month>06</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1865-8652</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Advances in therapy</Title><ISOAbbreviation>Adv Ther</ISOAbbreviation></Journal><ArticleTitle>Glycaemic and Weight Control in People Aged 65 or Younger Newly Diagnosed with Type 2 Diabetes in Spain: Insights from the PRIORITY-T2D Study.</ArticleTitle><Pagination><StartPage>3354</StartPage><EndPage>3368</EndPage><MedlinePgn>3354-3368</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12325-025-03230-7</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The objective of this study was to determine the number of people within glycated haemoglobin (HbA1c) targets and achieving weight-loss goals during the first 5&#xa0;years after type 2 diabetes (T2D) diagnosis and to explore the relationship between early weight loss and glycaemic control in routine care in Spain.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This was an observational retrospective study using IQVIA's electronic medical record database, including adults aged&#xa0;&#x2264;&#xa0;65&#xa0;years newly diagnosed with T2D. Variables included baseline sociodemographic/clinical characteristics, yearly HbA1c and weight data, and treatment patterns. Descriptive statistics and regression analyses were used.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 8973 people with T2D were included (mean age 53&#xa0;years; mean baseline HbA1c 7.7%; obesity at diagnosis: 64%). During the first 5&#xa0;years post-T2D diagnosis, 46-63% of the population did not have HbA1c&#xa0;&lt;&#xa0;6.5%, and&#xa0;&gt;&#xa0;60%, and&#xa0;&gt;&#xa0;80% of subjects did not achieve&#xa0;&#x2265;&#xa0;5% and&#xa0;&#x2265;&#xa0;10% weight loss, respectively. Early weight loss goal achievement (1st year after diagnosis) and weight loss magnitude were associated with a higher percentage of people with HbA1c&#xa0;&lt;&#xa0;6.5%.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Many individuals with T2D did not have HbA1c&#xa0;&lt;&#xa0;6.5% in the first 5&#xa0;years after diagnosis and did not achieve&#xa0;&#x2265;&#xa0;5% or&#xa0;&#x2265;&#xa0;10% weight loss. Early weight loss after T2D diagnosis was associated with higher likelihood of achieving early glycaemic control.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ortega</LastName><ForeName>Emilio</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-2217-8905</Identifier><AffiliationInfo><Affiliation>Diabetes Unit, Department of Endocrinology and Nutrition, Hospital Cl&#xed;nic, C. de Villarroel, 170, L'Eixample, 08036, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de la Fisiopatolog&#xed;a de la Obesidad y Nutrici&#xf3;n, Instituto de Salud Carlos III, Monforte de Lemos, 3-5, 28029, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut d'Investigacions, Hospital Cl&#xed;nic, Biom&#xe8;diques August Pi i Sunyer, C. de Villarroel, 170, L'Eixample, 08036, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Redondo-Ant&#xf3;n</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-2661-5866</Identifier><AffiliationInfo><Affiliation>Eli Lilly and Company, Av. de la Industria, 30, Alcobendas, 28108, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xed;az-Cerezo</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-6351-818X</Identifier><AffiliationInfo><Affiliation>Eli Lilly and Company, Av. de la Industria, 30, Alcobendas, 28108, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rubio-de Santos</LastName><ForeName>Miriam</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7393-6334</Identifier><AffiliationInfo><Affiliation>Eli Lilly and Company, Av. de la Industria, 30, Alcobendas, 28108, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romera</LastName><ForeName>Irene</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-1345-9799</Identifier><AffiliationInfo><Affiliation>Eli Lilly and Company, Av. de la Industria, 30, Alcobendas, 28108, Madrid, Spain. romera_irene@lilly.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Adv Ther</MedlineTA><NlmUniqueID>8611864</NlmUniqueID><ISSNLinking>0741-238X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006442">Glycated Hemoglobin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006442" MajorTopicYN="Y">Glycated Hemoglobin</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015431" MajorTopicYN="Y">Weight Loss</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000085002" MajorTopicYN="Y">Glycemic Control</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009765" MajorTopicYN="Y">Obesity</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="plain-language-summary" Language="eng"><AbstractText>This study looked at how many people with type 2 diabetes met blood glucose targets and weight-loss goals in the first 5&#xa0;years after their diagnosis. It also explored the link between early weight loss and blood glucose control in regular healthcare settings in Spain. Researchers analysed data from electronic medical records, focussing on adults aged 65 or younger who were newly diagnosed with diabetes. The study looked at the characteristics of people with diabetes, yearly blood glucose levels (as reflected in their glycated haemoglobin levels), weight measurements, and treatment patterns. The study used statistical methods to summarise the data and find connections. The study included 8973 people with newly diagnosed type 2 diabetes, with an average age of 53&#xa0;years and an average starting glycated haemoglobin of 7.7%. About 64% had obesity at diagnosis. Over the first 5&#xa0;years, 46&#x2013;63% of people did not achieve glycated haemoglobin levels below 6.5%. Guidelines recommend glycated haemoglobin levels equal or below 7.0%, or 6.5% for people who can achieve this goal safely. Additionally, more than 60% did not lose at least 5% of their weight, and more than 80% did not lose at least 10%. Those who lost weight within the first year after diagnosis and lost more weight overall were more likely to achieve good blood glucose control. This study concluded that many people with type 2 diabetes did not achieve their blood glucose or weight-loss goals within 5&#xa0;years of diagnosis. However, losing a meaningful amount of weight early on was linked to better blood glucose control early in the disease.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Glycated haemoglobin</Keyword><Keyword MajorTopicYN="N">Health outcomes</Keyword><Keyword MajorTopicYN="N">Spain</Keyword><Keyword MajorTopicYN="N">Treatment patterns</Keyword><Keyword MajorTopicYN="N">Type 2 diabetes</Keyword><Keyword MajorTopicYN="N">Weight loss</Keyword></KeywordList><CoiStatement>Declarations. Conflicts of Interest: Emilio Ortega has received institutional grants from Eli Lilly and Novo Nordisk, consulting fees from Eli Lilly, honoraria for presentations, manuscript writing or educational events from Eli Lilly and Novo Nordisk, and support for meeting attendance and/or travel from Eli Lilly and Novo Nordisk. Jennifer Redondo-Ant&#xf3;n, Silvia D&#xed;az-Cerezo, Miriam Rubio-de Santos, and Irene Romera are employees and minor shareholders of Eli Lilly and Company, Spain. Ethical Approval: As this was an observational study that used previously collected data and did not impose any form of intervention, and the data were previously deidentified/anonymised to protect participant privacy, a formal Consent to Release Information form was not required. Permission was obtained to access and use data from this database. The study protocol was approved by the ethical review board of Hospital Clinic (Barcelona, Spain) (approval code HCB/2023/0287, dated 16 May 2023), as required by Spanish regulations related to healthcare observational studies. The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and are consistent with Good Pharmacoepidemiology Practices and applicable laws and regulations of Spain.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>24</Day><Hour>18</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>19</Day><Hour>12</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>19</Day><Hour>11</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>5</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40388088</ArticleId><ArticleId IdType="pmc">PMC12182470</ArticleId><ArticleId IdType="doi">10.1007/s12325-025-03230-7</ArticleId><ArticleId IdType="pii">10.1007/s12325-025-03230-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45:2753&#x2013;86. 10.2337/dci22-0034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10008140</ArticleId><ArticleId IdType="pubmed">36148880</ArticleId></ArticleIdList></Reference><Reference><Citation>Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm - 2023 Update. Endocr Pract. 2023;29:305&#x2013;40. 10.1016/j.eprac.2023.02.001.</Citation><ArticleIdList><ArticleId IdType="pubmed">37150579</ArticleId></ArticleIdList></Reference><Reference><Citation>Laiteerapong N, Ham SA, Gao Y, et al. The legacy effect in type 2 diabetes: Impact of early glycemic control on future complications (the Diabetes &amp; Aging Study). Diabetes Care. 2019;42:416&#x2013;26. 10.2337/dc17-1144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6385699</ArticleId><ArticleId IdType="pubmed">30104301</ArticleId></ArticleIdList></Reference><Reference><Citation>Laiteerapong N, Karter AJ, Moffet HH, et al. Ten-year hemoglobin A1c trajectories and outcomes in type 2 diabetes mellitus: The Diabetes &amp; Aging Study. J Diabetes Complications. 2017;31:94&#x2013;100. 10.1016/j.jdiacomp.2016.07.023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5209280</ArticleId><ArticleId IdType="pubmed">27503405</ArticleId></ArticleIdList></Reference><Reference><Citation>American Diabetes Association Professional Practice Committee. 8. Obesity and weight management for the prevention and treatment of type 2 diabetes: Standards of care in diabetes&#x2014;2024. Diabetes Care. 2024;47(Suppl 1):S145&#x2013;57. 10.2337/dc23-S008.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10725806</ArticleId><ArticleId IdType="pubmed">38078578</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone MA, Charpentier G, Doggen K, et al. Quality of care of people with type 2 diabetes in eight European countries: findings from the Guideline Adherence to Enhance Care (GUIDANCE) study. Diabetes Care. 2013;36:2628&#x2013;38. 10.2337/dc12-1759.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3747883</ArticleId><ArticleId IdType="pubmed">23628621</ArticleId></ArticleIdList></Reference><Reference><Citation>Mata-Cases M, Vlacho B, Real J, et al. Trends in the degree of control and treatment of cardiovascular risk factors in people with type 2 diabetes in a primary care setting in Catalonia during 2007&#x2013;2018. Front Endocrinol (Lausanne). 2021;12:810757. 10.3389/fendo.2021.810757.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8784522</ArticleId><ArticleId IdType="pubmed">35082758</ArticleId></ArticleIdList></Reference><Reference><Citation>Boye KS, Lage MJ, Shinde S, Thieu V, Bae JP. Trends in HbA1c and body mass index among individuals with type 2 diabetes: Evidence from a US database 2012&#x2013;2019. Diabetes Ther. 2021;12:2077&#x2013;87. 10.1007/s13300-021-01084-0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8266935</ArticleId><ArticleId IdType="pubmed">34076849</ArticleId></ArticleIdList></Reference><Reference><Citation>Galindo RJ, Uppal TS, McCoy RG, Umpierrez GE, Ali MK. Use and continuity of weight-modifying medications among adults with diabetes and overweight/obesity: US population study. Obesity (Silver Spring). 2023;31:2924&#x2013;35. 10.1002/oby.23869.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10840906</ArticleId><ArticleId IdType="pubmed">37919239</ArticleId></ArticleIdList></Reference><Reference><Citation>Ares-Blanco S, Polentino-Casreo E, Rodr&#xed;guez-Cabrera F, et al. Inequalities in glycemic and multifactorial cardiovascular control of type 2 diabetes: the Heart Healthy Hoods study. Front Med (Lausanne). 2022;9:966368. 10.3389/fmed.2022.966368.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9769119</ArticleId><ArticleId IdType="pubmed">36569128</ArticleId></ArticleIdList></Reference><Reference><Citation>Peral Mart&#xed;nez IM, Mart&#xed;nez Pastor A, Gomarez Garc&#xed;a JJ, et al. Regional differences in the degree of glycaemic diabetes control in Spain and associated factors. IBERICAN study. Endocrinol Diabetes Nutr (Engl Ed). 2023;70:448&#x2013;58. 10.1016/j.endien.2023.07.001.</Citation><ArticleIdList><ArticleId IdType="pubmed">37468414</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rez A, Redondo-Ant&#xf3;n J, Romera I, et al. Disease and economic burden of poor metabolic and weight control in type 2 diabetes in Spain: a systematic literature review. Diabetes Ther. 2024;15:325&#x2013;41. 10.1007/s13300-023-01503-4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10838877</ArticleId><ArticleId IdType="pubmed">37989829</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez A, Mediavilla JJ, Mi&#xf1;ambres I, Gonz&#xe1;les-Segura D. Glycemic control in patients with type 2 diabetes mellitus in Spain. Rev Clin Esp (Barc). 2014;214:429&#x2013;36. 10.1016/j.rce.2014.05.028.</Citation><ArticleIdList><ArticleId IdType="pubmed">25016415</ArticleId></ArticleIdList></Reference><Reference><Citation>Lind M, Imberg H, Coleman RL, Nerman O, Holman RR. Historical HbA(1c) values may explain the type 2 diabetes legacy effect: UKPDS 88. Diabetes Care. 2021;44:2231&#x2013;7. 10.2337/dc20-2439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8740943</ArticleId><ArticleId IdType="pubmed">34244332</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozing MP, M&#xf6;ller A, Aabenhus R, Siersma V, Rasmussen K, K&#xf8;ster-Rasmussen R. Changes in HbA1c during the first six years after the diagnosis of Type 2 diabetes mellitus predict long-term microvascular outcomes. PLoS ONE. 2019;14: e0225230. 10.1371/journal.pone.0225230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6881005</ArticleId><ArticleId IdType="pubmed">31774849</ArticleId></ArticleIdList></Reference><Reference><Citation>Riddle MC. Individualizing treatment of type 2 diabetes after metformin: more insights from GRADE. Diabetes Care. 2024;47:556&#x2013;61. 10.2337/dci24-0008.</Citation><ArticleIdList><ArticleId IdType="pubmed">38527123</ArticleId></ArticleIdList></Reference><Reference><Citation>Haghighatpanah M, Nejad AFM, Haghighatpanah M, Thunga G, Mallayasami S. Factors that correlate with poor glycemic control in type 2 diabetes mellitus patients with complications. Osong Public Health Res Perspect. 2018;9:167&#x2013;74. 10.24171/j.phrp.2018.9.4.05.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6110332</ArticleId><ArticleId IdType="pubmed">30159222</ArticleId></ArticleIdList></Reference><Reference><Citation>Shamshirgaran SM, Mamaghanian A, Aliasgarzadeh A, Aiminisani N, Iranpavar-Alamdari M, Ataie J. Age differences in diabetes-related complications and glycemic control. BMC Endocr Disord. 2017;17:25. 10.1186/s12902-017-0175-5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5418847</ArticleId><ArticleId IdType="pubmed">28472985</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman BS, Cohen-Stavi CJ, Leibowitz M, et al. Defining the role of medication adherence in poor glycemic control among a general adult population with diabetes. PLoS ONE. 2014;9: e108145. 10.1371/journal.pone.0108145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4178119</ArticleId><ArticleId IdType="pubmed">25259843</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojo-Martinez G, Vald&#xe9;z L, Soriguer F, et al. Incidence of diabetes mellitus in Spain as results of the nation-wide cohort di@bet.es study. Sci Rep. 2020;10:2765. 10.1038/s41598-020-59643-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7026031</ArticleId><ArticleId IdType="pubmed">32066839</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor R, Barnes AC, Hollingsworth KG, et al. Aetiology of Type 2 diabetes in people with a &#x201c;normal&#x201d; body mass index: testing the personal fat threshold hypothesis. Clin Sci (Lond). 2023;137:1333&#x2013;46. 10.1042/CS20230586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10472166</ArticleId><ArticleId IdType="pubmed">37593846</ArticleId></ArticleIdList></Reference><Reference><Citation>Norris SL, Zhang X, Avenell A, et al. Long-term non-pharmacologic weight loss interventions for adults with type 2 diabetes. Cochrane Database Syst Rev. 2005;2005:CD004095. 10.1002/14651858.CD004095.pub2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8407357</ArticleId><ArticleId IdType="pubmed">15846698</ArticleId></ArticleIdList></Reference><Reference><Citation>Look AHEAD Research Group. Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study. Obesity (Silver Spring). 2014;22:5&#x2013;13. 10.1002/oby.20662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3904491</ArticleId><ArticleId IdType="pubmed">24307184</ArticleId></ArticleIdList></Reference><Reference><Citation>Lean ME, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018;391:541&#x2013;51. 10.1016/S0140-6736(17)33102-1.</Citation><ArticleIdList><ArticleId IdType="pubmed">29221645</ArticleId></ArticleIdList></Reference><Reference><Citation>Lean ME, Leslie WS, Barnes AC, et al. 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study. Lancet Diabetes Endocrinol. 2024;12:233&#x2013;46. 10.1016/S2213-8587(23)00385-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">38423026</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregg EW, Chen H, Bancks MP, et al. Impact of remission from type 2 diabetes on long-term health outcomes: findings from the Look AHEAD study. Diabetologia. 2024;67:459&#x2013;69. 10.1007/s00125-023-06048-6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10844408</ArticleId><ArticleId IdType="pubmed">38233592</ArticleId></ArticleIdList></Reference><Reference><Citation>Busetto L, Bettini S, Makaronidis J, Roberts CA, Halford JCG, Batterham RL. Mechanisms of weight regain. Eur J Intern Med. 2021;93:3&#x2013;7. 10.1016/j.ejim.2021.01.002.</Citation><ArticleIdList><ArticleId IdType="pubmed">33461826</ArticleId></ArticleIdList></Reference><Reference><Citation>Khunti K, Gomes MB, Pocock S, et al. Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review. Diabetes Obes Metab. 2018;20:427&#x2013;37. 10.1111/dom.13088.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5813232</ArticleId><ArticleId IdType="pubmed">28834075</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinde S, Thieu VT, Kwan AYM, Houghton K, Meyers J, Schapiro D. Impact of weight change on glycemic control and metabolic parameters in T2D: A retrospective US study based on real-world data. Diabetes Ther. 2024;15:409&#x2013;26. 10.1007/s13300-023-01511-4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10838891</ArticleId><ArticleId IdType="pubmed">38038898</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40221023</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0210-5705</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>8</Issue><PubDate><Year>2025</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Gastroenterologia y hepatologia</Title><ISOAbbreviation>Gastroenterol Hepatol</ISOAbbreviation></Journal><ArticleTitle>Multidisciplinary clinical practice guideline on the management of metabolic hepatic steatosis.</ArticleTitle><Pagination><StartPage>502442</StartPage><MedlinePgn>502442</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.gastrohep.2025.502442</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0210-5705(25)00118-9</ELocationID><Abstract><AbstractText>Metabolic hepatic steatosis (MetHS) is a clinically heterogeneous, multisystemic, dynamic, and complex disease, whose progression is one of the main causes of cirrhosis and hepatocarcinoma. This clinical practice guideline aims to respond to its main challenges, both in terms of disease burden and complexity. To this end, recommendations have been proposed to experts through the Delphi method. The consensus was optimal in recommendations regarding type 2 diabetes as a risk factor (1.5.1, 4.5.1), in which cases early detection of MetHS should be carried out (4.5.2). Its results also emphasize the importance of the use of non-invasive tests (FIB-4, NFS, HFS) for the exclusion of significant fibrosis in patients with suspected MetHS (2.3.1, 2.3.3). Diagnosis should be carried out through the sequential combination of non-invasive indices and transient elastography by FibroScan&#xae; for its risk stratification (2.3.3). A nearly unanimous consensus was reached regarding the role of early prevention in the impact on the quality of life and survival of patients (5.1.2), as well as on the effectiveness of the Mediterranean diet and physical exercise in relation to the improvement of steatosis, steatohepatitis and fibrosis in MetHS patients (5.2.2) and on the positive results offered by resmiterom and semaglutide in promoting fibrosis regression (5.4.1). Finally, a great consensus has been reached regarding the importance of multidisciplinary management in MetHS, for which it is essential to agree on multidisciplinary protocols for referral between levels in each health area (6.2.1), as well as ensuring that referrals to Hepatology/Digestive and Endocrinology or Internal Medicine services are effective and beneficial to prevent the risk of disease progression (6.2.3, 6.3.1).</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Romero-G&#xf3;mez</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>UGC Aparato Digestivo, Hospital Universitario Virgen del Roc&#xed;o, Sevilla, Espa&#xf1;a; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Hep&#xe1;ticas y Digestivas (CIBEREHD), Madrid, Espa&#xf1;a; Instituto de Biomedicina de Sevilla (HUVR/CSIC/US), Departamento de Medicina, Universidad de Sevilla, Sevilla, Espa&#xf1;a; Asociaci&#xf3;n Espa&#xf1;ola para el Estudio del H&#xed;gado, Espa&#xf1;a. Electronic address: mromerogomez@us.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Escalada</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sociedad Espa&#xf1;ola de Endocrinolog&#xed;a y Nutrici&#xf3;n. Cl&#xed;nica Universidad de Navarra, Pamplona, Espa&#xf1;a; Sociedad Espa&#xf1;ola de Endocrinolog&#xed;a y Nutrici&#xf3;n, Madrid, Espa&#xf1;a; CIBER Fisiopatolog&#xed;a de la Obesidad y Nutrici&#xf3;n (CIBERObn), Instituto de Salud Carlos III, Madrid, Espa&#xf1;a; Instituto de Investigaci&#xf3;n en la Salud de Navarra (IdiSNA), Pamplona, Espa&#xf1;a. Electronic address: fjavier.escalada@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noguerol</LastName><ForeName>Mar</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centro de Salud Universitario Cuzco de Fuenlabrada, Madrid, Espa&#xf1;a; Sociedad Espa&#xf1;ola de Medicina de Familia y Comunitaria, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe9;rez</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Servicio de Endocrinolog&#xed;a y Nutrici&#xf3;n, Hospital de la Santa Creu i Sant Pau, Barcelona, Espa&#xf1;a; CIBER de Diabetes y Enfermedades Metab&#xf3;licas (CIBERDEM), Madrid, Espa&#xf1;a; Sociedad Espa&#xf1;ola de Diabetes, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carretero</LastName><ForeName>Juana</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hospital Universitario de Badajoz, Badajoz, Espa&#xf1;a; Sociedad Espa&#xf1;ola de Medicina Interna (SEMI), Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crespo</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hospital Universitario Marqu&#xe9;s de Valdecilla, Santander, Espa&#xf1;a; Sociedad Espa&#xf1;ola de Patolog&#xed;a Digestiva, Madrid, Espa&#xf1;a; Grupo de Investigaci&#xf3;n Cl&#xed;nica y Traslacional en Enfermedades Digestivas, Santander, Espa&#xf1;a; Instituto de Investigaci&#xf3;n Valdecilla (IDIVAL), Santander, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mascort</LastName><ForeName>Juan J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Sociedad Espa&#xf1;ola de Medicina de Familia y Comunitaria, Madrid, Espa&#xf1;a; Centro de Salud Florida Sud, Institut Catal&#xe0; de la Salut, Hospitalet de Llobregat, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aguilar</LastName><ForeName>Ignacio</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Centro de Salud Roquetas Norte, Roquetas de Mar, Almer&#xed;a, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tinahones</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>CIBER Fisiopatolog&#xed;a de la Obesidad y Nutrici&#xf3;n (CIBERObn), Instituto de Salud Carlos III, Madrid, Espa&#xf1;a; Departamento de Endocrinolog&#xed;a y Nutrici&#xf3;n, Hospital Virgen de la Victoria, M&#xe1;laga, Espa&#xf1;a; Sociedad Espa&#xf1;ola de Obesidad, Madrid, Espa&#xf1;a; Instituto de Investigaci&#xf3;n Biom&#xe9;dica de M&#xe1;laga (IBIMA)-Plataforma Bionard, Universidad de M&#xe1;laga, M&#xe1;laga, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ca&#xf1;ones</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Sociedad Espa&#xf1;ola de M&#xe9;dicos Generales y de Familia, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;mez-Huelgas</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Sociedad Espa&#xf1;ola de Medicina Interna (SEMI), Madrid, Espa&#xf1;a; Servicio de Medicina Interna, Hospital Regional Universitario de M&#xe1;laga, M&#xe1;laga, Espa&#xf1;a; Instituto de Investigaci&#xf3;n Biom&#xe9;dica de M&#xe1;laga (IBIMA), Universidad de M&#xe1;laga (UMA), M&#xe1;laga, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Luis</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Sociedad Espa&#xf1;ola de Endocrinolog&#xed;a y Nutrici&#xf3;n, Madrid, Espa&#xf1;a; Servicio de Endocrinolog&#xed;a y Nutrici&#xf3;n, Hospital Cl&#xed;nico Universitario de Valladolid, Valladolid, Espa&#xf1;a; Centro de Investigaci&#xf3;n de Endocrinolog&#xed;a y Nutrici&#xf3;n, Universidad de Valladolid, Valladolid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gen&#xfa;a Trullos</LastName><ForeName>Idoia</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Servicio de Endocrinolog&#xed;a y Nutrici&#xf3;n, Hospital de la Santa Creu i Sant Pau, Barcelona, Espa&#xf1;a; Sociedad Espa&#xf1;ola de Diabetes, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aller</LastName><ForeName>Roc&#xed;o</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Asociaci&#xf3;n Espa&#xf1;ola para el Estudio del H&#xed;gado, Espa&#xf1;a; Servicio de Endocrinolog&#xed;a y Nutrici&#xf3;n, Hospital de la Santa Creu i Sant Pau, Barcelona, Espa&#xf1;a; Sociedad Espa&#xf1;ola de Diabetes, Madrid, Espa&#xf1;a; Servicio de Aparato Digestivo, Hospital Cl&#xed;nico Universitario de Valladolid, Universidad de Valladolid, Valladolid, Espa&#xf1;a; Ciber Enfermedades infecciosas (CIBERINFEC), Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rubio</LastName><ForeName>Miguel A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Sociedad Espa&#xf1;ola de Endocrinolog&#xed;a y Nutrici&#xf3;n, Madrid, Espa&#xf1;a; Hospital Cl&#xed;nico San Carlos, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017065">Practice Guideline</PublicationType></PublicationTypeList><VernacularTitle>Gu&#xed;a de pr&#xe1;ctica cl&#xed;nica multidisciplinar de manejo de la esteatosis hep&#xe1;tica metab&#xf3;lica.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Gastroenterol Hepatol</MedlineTA><NlmUniqueID>8406671</NlmUniqueID><ISSNLinking>0210-5705</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005234" MajorTopicYN="Y">Fatty Liver</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065626" MajorTopicYN="Y">Non-alcoholic Fatty Liver Disease</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008103" MajorTopicYN="N">Liver Cirrhosis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003697" MajorTopicYN="N">Delphi Technique</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010348" MajorTopicYN="N">Patient Care Team</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Derivaci&#xf3;n</Keyword><Keyword MajorTopicYN="N">Detecci&#xf3;n</Keyword><Keyword MajorTopicYN="N">Detection</Keyword><Keyword MajorTopicYN="N">Esteatohepatitis</Keyword><Keyword MajorTopicYN="N">Esteatosis hep&#xe1;tica metab&#xf3;lica</Keyword><Keyword MajorTopicYN="N">Fibrosis</Keyword><Keyword MajorTopicYN="N">Metabolic hepatic steatosis</Keyword><Keyword MajorTopicYN="N">Referral</Keyword><Keyword MajorTopicYN="N">Steatohepatitis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>3</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>30</Day><Hour>5</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>13</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>12</Day><Hour>19</Hour><Minute>36</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40221023</ArticleId><ArticleId IdType="doi">10.1016/j.gastrohep.2025.502442</ArticleId><ArticleId IdType="pii">S0210-5705(25)00118-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39811651</PMID><DateRevised><Year>2025</Year><Month>01</Month><Day>29</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2589-0042</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jan</Month><Day>17</Day></PubDate></JournalIssue><Title>iScience</Title><ISOAbbreviation>iScience</ISOAbbreviation></Journal><ArticleTitle>Differences in splicing factors may predict type 2 diabetes remission in the CORDIOPREV study.</ArticleTitle><Pagination><StartPage>111527</StartPage><MedlinePgn>111527</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">111527</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.isci.2024.111527</ELocationID><Abstract><AbstractText>Alternative splicing is a post-transcriptional process resulting in multiple protein isoforms from a single gene. Abnormal splicing may lead to metabolic diseases, including type 2 diabetes mellitus (T2DM). To identify the splicing factor expression that predicts T2DM remission in coronary heart disease (CHD) patients, we identified newly diagnosed T2DM at baseline (<i>n</i>&#xa0;= 190) from the CORDIOPREV study. Patients were classified as Responders (T2DM remission during 5 years without antidiabetic drugs) or non-Responders. Baseline dysregulation in 5 splicing factors (<i>MBNL1</i>, <i>RBM5</i>, <i>hnRNP G/RBMX</i>, <i>CD44</i>, <i>NT5E</i>) distinguished Responders from non-Responders. Adding these factors to clinical variables [AUC&#xa0;= 0.67], insulin resistance, and beta-cell indexes [AUC&#xa0;= 0.76], improved T2DM remission prediction [AUC&#xa0;= 0.80]. Cox regression analysis showed those with higher remission scores had a 2.63-fold increased remission probability. To conclude, a set of splicing factors that contribute to predicting T2DM remission in patients with CHD has been identified. Further research is needed to elucidate these findings' clinical relevance.</AbstractText><CopyrightInformation>&#xa9; 2024 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ojeda-Rodriguez</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Lipids and Atherosclerosis Unit, Internal Medicine Unit, Reina Sofia University Hospital, 14004 Cordoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical and Surgical Science, University of Cordoba, 14004 C&#xf3;rdoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Av. Menendez Pidal, S/n, 14004 Cordoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER Fisiopatologia de La Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torres-Pe&#xf1;a</LastName><ForeName>Jose D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Lipids and Atherosclerosis Unit, Internal Medicine Unit, Reina Sofia University Hospital, 14004 Cordoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical and Surgical Science, University of Cordoba, 14004 C&#xf3;rdoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Av. Menendez Pidal, S/n, 14004 Cordoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER Fisiopatologia de La Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arenas-de Larriva</LastName><ForeName>Antonio Pablo</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Lipids and Atherosclerosis Unit, Internal Medicine Unit, Reina Sofia University Hospital, 14004 Cordoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical and Surgical Science, University of Cordoba, 14004 C&#xf3;rdoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Av. Menendez Pidal, S/n, 14004 Cordoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER Fisiopatologia de La Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rangel-Zu&#xf1;iga</LastName><ForeName>Oriol Alberto</ForeName><Initials>OA</Initials><AffiliationInfo><Affiliation>Lipids and Atherosclerosis Unit, Internal Medicine Unit, Reina Sofia University Hospital, 14004 Cordoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical and Surgical Science, University of Cordoba, 14004 C&#xf3;rdoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Av. Menendez Pidal, S/n, 14004 Cordoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER Fisiopatologia de La Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Podadera-Herreros</LastName><ForeName>Alicia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Lipids and Atherosclerosis Unit, Internal Medicine Unit, Reina Sofia University Hospital, 14004 Cordoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical and Surgical Science, University of Cordoba, 14004 C&#xf3;rdoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Av. Menendez Pidal, S/n, 14004 Cordoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER Fisiopatologia de La Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boughanem</LastName><ForeName>Hatim</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Lipids and Atherosclerosis Unit, Internal Medicine Unit, Reina Sofia University Hospital, 14004 Cordoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical and Surgical Science, University of Cordoba, 14004 C&#xf3;rdoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Av. Menendez Pidal, S/n, 14004 Cordoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER Fisiopatologia de La Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G-Garc&#xed;a</LastName><ForeName>Miguel E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Av. Menendez Pidal, S/n, 14004 Cordoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER Fisiopatologia de La Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell Biology, Physiology and Immunology, University of Cordoba, 14004 Cordoba, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez-Moreno</LastName><ForeName>Alejandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Lipids and Atherosclerosis Unit, Internal Medicine Unit, Reina Sofia University Hospital, 14004 Cordoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical and Surgical Science, University of Cordoba, 14004 C&#xf3;rdoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Av. Menendez Pidal, S/n, 14004 Cordoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER Fisiopatologia de La Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katsiki</LastName><ForeName>Niki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Nutritional Sciences and Dietetics, International Hellenic University, 57400 Thessaloniki, Greece.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, European University Cyprus, 2404 Nicosia, Cyprus, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luque</LastName><ForeName>Raul M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Av. Menendez Pidal, S/n, 14004 Cordoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER Fisiopatologia de La Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell Biology, Physiology and Immunology, University of Cordoba, 14004 Cordoba, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perez-Martinez</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Lipids and Atherosclerosis Unit, Internal Medicine Unit, Reina Sofia University Hospital, 14004 Cordoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical and Surgical Science, University of Cordoba, 14004 C&#xf3;rdoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Av. Menendez Pidal, S/n, 14004 Cordoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER Fisiopatologia de La Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delgado-Lista</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Lipids and Atherosclerosis Unit, Internal Medicine Unit, Reina Sofia University Hospital, 14004 Cordoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical and Surgical Science, University of Cordoba, 14004 C&#xf3;rdoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Av. Menendez Pidal, S/n, 14004 Cordoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER Fisiopatologia de La Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yubero-Serrano</LastName><ForeName>Elena M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Lipids and Atherosclerosis Unit, Internal Medicine Unit, Reina Sofia University Hospital, 14004 Cordoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical and Surgical Science, University of Cordoba, 14004 C&#xf3;rdoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Av. Menendez Pidal, S/n, 14004 Cordoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER Fisiopatologia de La Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Food and Health, Instituto de La Grasa, Spanish National Research Council (CSIC), 41013 Seville, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez-Miranda</LastName><ForeName>Jose</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Lipids and Atherosclerosis Unit, Internal Medicine Unit, Reina Sofia University Hospital, 14004 Cordoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical and Surgical Science, University of Cordoba, 14004 C&#xf3;rdoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Av. Menendez Pidal, S/n, 14004 Cordoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER Fisiopatologia de La Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>12</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>iScience</MedlineTA><NlmUniqueID>101724038</NlmUniqueID><ISSNLinking>2589-0042</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiovascular medicine</Keyword><Keyword MajorTopicYN="N">Human metabolism</Keyword><Keyword MajorTopicYN="N">Public health</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>1</Month><Day>15</Day><Hour>4</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>12</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39811651</ArticleId><ArticleId IdType="pmc">PMC11731613</ArticleId><ArticleId IdType="doi">10.1016/j.isci.2024.111527</ArticleId><ArticleId IdType="pii">S2589-0042(24)02754-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>James S.L., Abate D., Abate K.H., Abay S.M., Abbafati C., Abbasi N., Abbastabar H., Abd-Allah F., Abdela J., Abdelalim A., Abdollahpour I. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990&#x2013;2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789&#x2013;1858. doi: 10.1016/S0140-6736(18)32279-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)32279-7</ArticleId><ArticleId IdType="pmc">PMC6227754</ArticleId><ArticleId IdType="pubmed">30496104</ArticleId></ArticleIdList></Reference><Reference><Citation>Giri B., Dey S., Das T., Sarkar M., Banerjee J., Dash S.K. Chronic hyperglycemia mediated physiological alteration and metabolic distortion leads to organ dysfunction, infection, cancer progression and other pathophysiological consequences: An update on glucose toxicity. Biomed. Pharmacother. 2018;107:306&#x2013;328. doi: 10.1016/j.biopha.2018.07.157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2018.07.157</ArticleId><ArticleId IdType="pubmed">30098549</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsiki N., Anagnostis P., Kotsa K., Goulis D.G., Mikhailidis D.P. Obesity, Metabolic Syndrome and the Risk of Microvascular Complications in Patients with Diabetes mellitus. Curr. Pharmaceut. Des. 2019;25:2051&#x2013;2059.</Citation><ArticleIdList><ArticleId IdType="pubmed">31298151</ArticleId></ArticleIdList></Reference><Reference><Citation>Bondar A., Popa A.R., Papanas N., Popoviciu M., Vesa C.M., Sabau M., Daina C., Stoica R.A., Katsiki N., Stoian A.P. Diabetic neuropathy: A narrative review of risk factors, classification, screening and current pathogenic treatment options (Review) Exp. Ther. Med. 2021;22 doi: 10.3892/etm.2021.10122.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2021.10122</ArticleId><ArticleId IdType="pmc">PMC8111877</ArticleId><ArticleId IdType="pubmed">33986855</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma C.X., Ma X.N., Guan C.H., Li Y.D., Mauricio D., Fu S.B. Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management. Cardiovasc. Diabetol. 2022;21:74. doi: 10.1186/s12933-022-01516-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-022-01516-6</ArticleId><ArticleId IdType="pmc">PMC9107726</ArticleId><ArticleId IdType="pubmed">35568946</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsiki N., Mikhailidis D.P. Diabetes and carotid artery disease: a narrative review. Ann. Transl. Med. 2020;8:1280. doi: 10.21037/atm.2019.12.153.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/atm.2019.12.153</ArticleId><ArticleId IdType="pmc">PMC7607073</ArticleId><ArticleId IdType="pubmed">33178812</ArticleId></ArticleIdList></Reference><Reference><Citation>Triposkiadis F., Xanthopoulos A., Bargiota A., Kitai T., Katsiki N., Farmakis D., Skoularigis J., Starling R.C., Iliodromitis E. Diabetes mellitus and heart failure. J.&#xa0;Clin. Med. 2021;10 doi: 10.3390/jcm10163682.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10163682</ArticleId><ArticleId IdType="pmc">PMC8396967</ArticleId><ArticleId IdType="pubmed">34441977</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsiki N., Perez-Martinez P., Anagnostis P., Mikhailidis D.P., Karagiannis A. Is Nonalcoholic Fatty Liver Disease Indeed the Hepatic Manifestation of Metabolic Syndrome? Curr. Vasc. Pharmacol. 2018;16:219&#x2013;227. doi: 10.2174/1570161115666170621075619.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570161115666170621075619</ArticleId><ArticleId IdType="pubmed">28669328</ArticleId></ArticleIdList></Reference><Reference><Citation>Standars of Care in Diabetes-2024. Diabetes Care. 2024;47:S1&#x2013;S321. doi: 10.2337/dc24-SINT.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc24-SINT</ArticleId><ArticleId IdType="pmc">PMC10725799</ArticleId><ArticleId IdType="pubmed">38078587</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMarsilis A., Reddy N., Boutari C., Filippaios A., Sternthal E., Katsiki N., Mantzoros C. Pharmacotherapy of type 2 diabetes: An update and future directions. Metabolism. 2022;137 doi: 10.1016/j.metabol.2022.155332.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metabol.2022.155332</ArticleId><ArticleId IdType="pubmed">36240884</ArticleId></ArticleIdList></Reference><Reference><Citation>Roglic G., World Health Organization . Global Report on Diabetes. World Health Organization; Geneva: 2016.</Citation></Reference><Reference><Citation>Watts M.  2023. Reversing Type 2 Diabetes.https://www.diabetes.co.uk/reversing-diabetes.html</Citation></Reference><Reference><Citation>Shibib L., Al-Qaisi M., Ahmed A., Miras A.D., Nott D., Pelling M., Greenwald S.E., Guess N. Reversal and Remission of T2DM&#xa0;&#x2013; An Update for Practitioners. Vasc. Health Risk Manag. 2022;18:417&#x2013;443. doi: 10.2147/VHRM.S345810.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/VHRM.S345810</ArticleId><ArticleId IdType="pmc">PMC9206440</ArticleId><ArticleId IdType="pubmed">35726218</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly J., Karlsen M., Steinke G. Type 2 Diabetes Remission and Lifestyle Medicine: A Position Statement From the American College of Lifestyle Medicine. Am. J. Lifestyle Med. 2020;14:406&#x2013;419. doi: 10.1177/1559827620930962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1559827620930962</ArticleId><ArticleId IdType="pmc">PMC7692017</ArticleId><ArticleId IdType="pubmed">33281521</ArticleId></ArticleIdList></Reference><Reference><Citation>Roncero-Ramos I., Gutierrez-Mariscal F.M., Gomez-Delgado F., Villasanta-Gonzalez A., Torres-Pe&#xf1;a J.D., Cruz-Ares S.D.L., Rangel-Zu&#xf1;iga O.A., Luque R.M., Ordovas J.M., Delgado-Lista J., et al. Beta cell functionality and hepatic insulin resistance are major contributors to type 2 diabetes remission and starting pharmacological therapy: from CORDIOPREV randomized controlled trial. Transl. Res. 2021;238:12&#x2013;24. doi: 10.1016/j.trsl.2021.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2021.07.001</ArticleId><ArticleId IdType="pubmed">34298148</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardelo M.P., Alcala-Diaz J.F., Gutierrez-Mariscal F.M., Lopez-Moreno J., Villasanta-Gonzalez A., Arenas-de Larriva A.P., Cruz-Ares S.d.l., Delgado-Lista J., Rodriguez-Cantalejo F., Luque R.M., et al. Diabetes Remission Is Modulated by Branched Chain Amino Acids According to the Diet Consumed: From the CORDIOPREV Study. Mol. Nutr. Food Res. 2022;66 doi: 10.1002/mnfr.202100652.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mnfr.202100652</ArticleId><ArticleId IdType="pubmed">34863046</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutierrez-Mariscal F.M., Cardelo M.P., de la Cruz S., Alcala-Diaz J.F., Roncero-Ramos I., Guler I., Vals-Delgado C., L&#xf3;pez-Moreno A., Luque R.M., Delgado-Lista J., et al. Reduction in Circulating Advanced Glycation End Products by Mediterranean Diet Is Associated with Increased Likelihood of Type 2 Diabetes Remission in Patients with Coronary Heart Disease: From the Cordioprev Study. Mol. Nutr. Food Res. 2021;65 doi: 10.1002/mnfr.201901290.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mnfr.201901290</ArticleId><ArticleId IdType="pubmed">32529753</ArticleId></ArticleIdList></Reference><Reference><Citation>Mora-Ortiz M., Alcala-Diaz J.F., Rangel-Zu&#xf1;iga O.A., Arenas-de Larriva A.P., Abollo-Jimenez F., Luque-Cordoba D., Priego-Capote F., Malagon M.M., Delgado-Lista J., Ordovas J.M., et al. Metabolomics analysis of type 2 diabetes remission identifies 12 metabolites with predictive capacity: a CORDIOPREV clinical trial study. BMC Med. 2022;20:373. doi: 10.1186/s12916-022-02566-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-022-02566-z</ArticleId><ArticleId IdType="pmc">PMC9609192</ArticleId><ArticleId IdType="pubmed">36289459</ArticleId></ArticleIdList></Reference><Reference><Citation>Vals-Delgado C., Alcala-Diaz J.F., Roncero-Ramos I., Leon-Acu&#xf1;a A., Molina-Abril H., Gutierrez-Mariscal F.M., Romero-Cabrera J.L., de la Cruz-Ares S., van Ommen B., Casta&#xf1;o J.P., et al. A microbiota-based predictive model for type 2 diabetes remission induced by dietary intervention: From the CORDIOPREV study. Clin. Transl. Med. 2021;11:e326&#x2013;e328. doi: 10.1002/ctm2.326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ctm2.326</ArticleId><ArticleId IdType="pmc">PMC8023646</ArticleId><ArticleId IdType="pubmed">33931973</ArticleId></ArticleIdList></Reference><Reference><Citation>Rangel-Zu&#xf1;iga O.A., Vals-Delgado C., Alcala-Diaz J.F., Quintana-Navarro G.M., Krylova Y., Leon-Acu&#xf1;a A., Luque R.M., Gomez-Delgado F., Delgado-Lista J., Ordovas J.M., et al. A set of miRNAs predicts T2DM remission in patients with coronary heart disease: from the CORDIOPREV study. Mol. Ther. Nucleic Acids. 2021;23:255&#x2013;263. doi: 10.1016/j.omtn.2020.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2020.11.001</ArticleId><ArticleId IdType="pmc">PMC7770508</ArticleId><ArticleId IdType="pubmed">33425484</ArticleId></ArticleIdList></Reference><Reference><Citation>Gahete M.D., del Rio-Moreno M., Camargo A., Alcala-Diaz J.F., Alors-Perez E., Delgado-Lista J., Reyes O., Ventura S., Perez-Mart&#xed;nez P., Casta&#xf1;o J.P., et al. Changes in Splicing Machinery Components Influence, Precede, and Early Predict the Development of Type 2 Diabetes: From the CORDIOPREV Study. EBioMedicine. 2018;37:356&#x2013;365. doi: 10.1016/j.ebiom.2018.10.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2018.10.056</ArticleId><ArticleId IdType="pmc">PMC6286259</ArticleId><ArticleId IdType="pubmed">30446432</ArticleId></ArticleIdList></Reference><Reference><Citation>del R&#xed;o-Moreno M., Luque R.M., Rangel-Z&#xfa;&#xf1;iga O.A., Alors-P&#xe9;rez E., Alcal&#xe1;-Diaz J.F., Roncero-Ramos I., Camargo A., Gahete M.D., L&#xf3;pez-Miranda J., Casta&#xf1;o J.P. Dietary intervention modulates the expression of splicing machinery in cardiovascular patients at high risk of type 2 diabetes development: From the CORDIOPREV study. Nutrients. 2020;12:1&#x2013;14. doi: 10.3390/nu12113528.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12113528</ArticleId><ArticleId IdType="pmc">PMC7696699</ArticleId><ArticleId IdType="pubmed">33212780</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright C.J., Smith C.W.J., Jiggins C.D. Alternative splicing as a source of phenotypic diversity. Nat. Rev. Genet. 2022;23:697&#x2013;710. doi: 10.1038/s41576-022-00514-4. Published online.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41576-022-00514-4</ArticleId><ArticleId IdType="pubmed">35821097</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao Y., Zhang Q., Wang H., Yang X., Mu H. Alternative splicing and related RNA binding proteins in human health and disease. Signal Transduct. Targeted Ther. 2024;9 doi: 10.1038/s41392-024-01734-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-024-01734-2</ArticleId><ArticleId IdType="pmc">PMC10835012</ArticleId><ArticleId IdType="pubmed">38302461</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q., Fang L., Wu C. Alternative Splicing and Isoforms: From Mechanisms to Diseases. Genes. 2022;13 doi: 10.3390/genes13030401.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes13030401</ArticleId><ArticleId IdType="pmc">PMC8951537</ArticleId><ArticleId IdType="pubmed">35327956</ArticleId></ArticleIdList></Reference><Reference><Citation>Dlamini Z., Mokoena F., Hull R. Abnormalities in alternative splicing in diabetes: Therapeutic targets. J.&#xa0;Mol. Endocrinol. 2017;59:R93&#x2013;R107. doi: 10.1530/JME-17-0049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/JME-17-0049</ArticleId><ArticleId IdType="pubmed">28716821</ArticleId></ArticleIdList></Reference><Reference><Citation>Escribano O., Beneit N., Rubio-Long&#xe1;s C., L&#xf3;pez-Pastor A.R., G&#xf3;mez-Hern&#xe1;ndez A. The Role of Insulin Receptor Isoforms in Diabetes and Its Metabolic and Vascular Complications. J.&#xa0;Diabetes Res. 2017;2017 doi: 10.1155/2017/1403206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/1403206</ArticleId><ArticleId IdType="pmc">PMC5671728</ArticleId><ArticleId IdType="pubmed">29201918</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L.F., Kodama K., Wei K., Tolentino L.L., Choi O., Engleman E.G., Butte A.J., McLaughlin T. The receptor CD44 is associated with systemic insulin resistance and proinflammatory macrophages in human adipose tissue. Diabetologia. 2015;58:1579&#x2013;1586. doi: 10.1007/s00125-015-3603-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-015-3603-y</ArticleId><ArticleId IdType="pubmed">25952479</ArticleId></ArticleIdList></Reference><Reference><Citation>Kodama K., Horikoshi M., Toda K., Yamada S., Hara K., Irie J., Sirota M., Morgan A.A., Chen R., Ohtsu H., et al. Expression-based genome-wide association study links the receptor CD44 in adipose tissue with type 2 diabetes. Proc. Natl. Acad. Sci. USA. 2012;109:7049&#x2013;7054. doi: 10.1073/pnas.1114513109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1114513109</ArticleId><ArticleId IdType="pmc">PMC3344989</ArticleId><ArticleId IdType="pubmed">22499789</ArticleId></ArticleIdList></Reference><Reference><Citation>Fadista J., Vikman P., Laakso E.O., Mollet I.G., Esguerra J.L., Taneera J., Storm P., Osmark P., Ladenvall C., Prasad R.B., et al. Global genomic and transcriptomic analysis of human pancreatic islets reveals novel genes influencing glucose metabolism. Proc. Natl. Acad. Sci. USA. 2014;111:13924&#x2013;13929. doi: 10.1073/pnas.1402665111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1402665111</ArticleId><ArticleId IdType="pmc">PMC4183326</ArticleId><ArticleId IdType="pubmed">25201977</ArticleId></ArticleIdList></Reference><Reference><Citation>Matera A.G., Wang Z. A day in the life of the spliceosome. Nat. Rev. Mol. Cell Biol. 2014;15:108&#x2013;121. doi: 10.1038/nrm3742.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm3742</ArticleId><ArticleId IdType="pmc">PMC4060434</ArticleId><ArticleId IdType="pubmed">24452469</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy A.J., Li A.H., Li P., Sun H. Therapeutic Targeting of Alternative Splicing: A New Frontier in Cancer Treatment. Front. Oncol. 2022;12 doi: 10.3389/fonc.2022.868664.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2022.868664</ArticleId><ArticleId IdType="pmc">PMC9027816</ArticleId><ArticleId IdType="pubmed">35463320</ArticleId></ArticleIdList></Reference><Reference><Citation>del R&#xed;o-Moreno M., Alors-P&#xe9;rez E., Gonz&#xe1;lez-Rubio S., Ferr&#xed;n G., Reyes O., Rodr&#xed;guez-Per&#xe1;lvarez M., S&#xe1;nchez-Fr&#xed;as M.E., S&#xe1;nchez-S&#xe1;nchez R., Ventura S., L&#xf3;pez-Miranda J., Kineman R.D. Dysregulation of the Splicing Machinery Is Associated to the Development of Nonalcoholic Fatty Liver Disease. J.&#xa0;Clin. Endocrinol. Metab. 2019;104:3389&#x2013;3402. doi: 10.1210/jc.2019-00021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2019-00021</ArticleId><ArticleId IdType="pmc">PMC6590982</ArticleId><ArticleId IdType="pubmed">30901032</ArticleId></ArticleIdList></Reference><Reference><Citation>Juan-Mateu J., Villate O., Eizirik D.L. Alternative splicing: The new frontier in diabetes research. Eur. J. Endocrinol. 2016;174:R225&#x2013;R238. doi: 10.1530/EJE-15-0916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/EJE-15-0916</ArticleId><ArticleId IdType="pmc">PMC5331159</ArticleId><ArticleId IdType="pubmed">26628584</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson T.C., Kochanek P.M. RNA Binding Motif 5 (RBM5) in the CNS&#x2014;Moving Beyond Cancer to Harness RNA Splicing to Mitigate the Consequences of Brain Injury. Front. Mol. Neurosci. 2020;13 doi: 10.3389/fnmol.2020.00126.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2020.00126</ArticleId><ArticleId IdType="pmc">PMC7381114</ArticleId><ArticleId IdType="pubmed">32765218</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson T.C., Janesko-Feldman K., Gorse K., Vagni V.A., Jackson E.K., Kochanek P.M. Identification of Novel Targets of RBM5 in the Healthy and Injured Brain. Neuroscience. 2020;440:299&#x2013;315. doi: 10.1016/j.neuroscience.2020.04.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2020.04.024</ArticleId><ArticleId IdType="pmc">PMC8092805</ArticleId><ArticleId IdType="pubmed">32335213</ArticleId></ArticleIdList></Reference><Reference><Citation>Prabhu V.V., Devaraj N. Regulating RNA Binding Motif 5 Gene Expression- A Novel Therapeutic Target for Lung Cancer. J.&#xa0;Environ. Pathol. Toxicol. Oncol. 2017;36:99&#x2013;105. doi: 10.1615/JEnvironPatholToxicolOncol.2017019366.</Citation><ArticleIdList><ArticleId IdType="doi">10.1615/JEnvironPatholToxicolOncol.2017019366</ArticleId><ArticleId IdType="pubmed">29199590</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Yang J., Ni R., Chen J., Zhou Y., Song H., Jin L., Pan Y. Hypoxia-induced lncRNA RBM5-AS1 promotes tumorigenesis via activating Wnt/&#x3b2;-catenin signaling in breast cancer. Cell Death Dis. 2022;13 doi: 10.1038/s41419-022-04536-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-022-04536-y</ArticleId><ArticleId IdType="pmc">PMC8810931</ArticleId><ArticleId IdType="pubmed">35110544</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao C., Zheng Y., J&#xf6;nsson J., Cui X., Yu H., Wu C., Kajitani N., Schwartz S. hnRNP G/RBMX enhances HPV16 E2 mRNA splicing through a novel splicing enhancer and inhibits production of spliced E7 oncogene mRNAs. Nucleic Acids Res. 2022;50:3867&#x2013;3891. doi: 10.1093/nar/gkac213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkac213</ArticleId><ArticleId IdType="pmc">PMC9023273</ArticleId><ArticleId IdType="pubmed">35357488</ArticleId></ArticleIdList></Reference><Reference><Citation>Adamson B., Smogorzewska A., Sigoillot F.D., King R.W., Elledge S.J. A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response. Nat. Cell Biol. 2012;14:318&#x2013;328. doi: 10.1038/ncb2426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb2426</ArticleId><ArticleId IdType="pmc">PMC3290715</ArticleId><ArticleId IdType="pubmed">22344029</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu C., Wang L., Wei L. RNA-binding proteins in diabetic microangiopathy. J.&#xa0;Clin. Lab. Anal. 2022;36 doi: 10.1002/jcla.24407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcla.24407</ArticleId><ArticleId IdType="pmc">PMC9102490</ArticleId><ArticleId IdType="pubmed">35385161</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang X., lei R.X., xue X.Y., Yang S., Shi M., Wang L ning. Metformin Reduces the Senescence of Renal Tubular Epithelial Cells in Diabetic Nephropathy via the MBNL1/miR-130a-3p/STAT3 Pathway. Oxid. Med. Cell. Longev. 2020;2020 doi: 10.1155/2020/8708236.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/8708236</ArticleId><ArticleId IdType="pmc">PMC7035567</ArticleId><ArticleId IdType="pubmed">32104542</ArticleId></ArticleIdList></Reference><Reference><Citation>Sen S., Talukdar I., Liu Y., Tam J., Reddy S., Webster N.J.G. Muscleblind-like 1 (Mbnl1) promotes insulin receptor exon 11 inclusion via binding to a downstream evolutionarily conserved intronic enhancer. J.&#xa0;Biol. Chem. 2010;285:25426&#x2013;25437. doi: 10.1074/jbc.M109.095224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.095224</ArticleId><ArticleId IdType="pmc">PMC2919106</ArticleId><ArticleId IdType="pubmed">20519504</ArticleId></ArticleIdList></Reference><Reference><Citation>Malakar P., Chartarifsky L., Hija A., Leibowitz G., Glaser B., Dor Y., Karni R. Insulin receptor alternative splicing is regulated by insulin signaling and modulates beta cell survival. Sci. Rep. 2016;6 doi: 10.1038/srep31222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep31222</ArticleId><ArticleId IdType="pmc">PMC4985653</ArticleId><ArticleId IdType="pubmed">27526875</ArticleId></ArticleIdList></Reference><Reference><Citation>Park S., Kim O.H., Lee K., Park I.B., Kim N.H., Moon S., Im J., Sharma S.P., Oh B.C., Nam S., Lee D.H. Plasma and urinary extracellular vesicle microRNAs and their related pathways in diabetic kidney disease. Genomics. 2022;114 doi: 10.1016/j.ygeno.2022.110407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygeno.2022.110407</ArticleId><ArticleId IdType="pubmed">35716820</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappelli C., Tellez A., Jara C., Alarc&#xf3;n S., Torres A., Mendoza P., Podest&#xe1; L., Flores C., Quezada C., Oyarz&#xfa;n C., San Mart&#xed;n R. The TGF-&#x3b2; profibrotic cascade targets ecto-5&#x2032;-nucleotidase gene in proximal tubule epithelial cells and is a traceable marker of progressive diabetic kidney disease. Biochim. Biophys. Acta, Mol. Basis Dis. 2020;1866 doi: 10.1016/j.bbadis.2020.165796.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2020.165796</ArticleId><ArticleId IdType="pubmed">32289379</ArticleId></ArticleIdList></Reference><Reference><Citation>Delgado-Lista J., Perez-Martinez P., Garcia-Rios A., Alcala-Diaz J.F., Perez-Caballero A.I., Gomez-Delgado F., Fuentes F., Quintana-Navarro G., Lopez-Segura F., Ortiz-Morales A.M., et al. CORonary Diet Intervention with Olive oil and cardiovascular PREVention study (the CORDIOPREV study): Rationale, methods, and baseline characteristics A clinical trial comparing the efficacy of a Mediterranean diet rich in olive oil versus a low-fat diet on cardiovascular disease in coronary patients. Am. Heart J. 2016;177:42&#x2013;50. doi: 10.1016/j.ahj.2016.04.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2016.04.011</ArticleId><ArticleId IdType="pmc">PMC4910622</ArticleId><ArticleId IdType="pubmed">27297848</ArticleId></ArticleIdList></Reference><Reference><Citation>Delgado-Lista J., Alcala-Diaz J.F., Torres-Pe&#xf1;a J.D., Quintana-Navarro G.M., Fuentes F., Garcia-Rios A., Ortiz-Morales A.M., Gonzalez-Requero A.I., Perez-Caballero A.I., Yubero-Serrano E.M., et al. Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial. Lancet. 2022;399:1876&#x2013;1885. doi: 10.1016/S0140-6736(22)00122-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00122-2</ArticleId><ArticleId IdType="pubmed">35525255</ArticleId></ArticleIdList></Reference><Reference><Citation>American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37:81&#x2013;90. doi: 10.2337/dc14-S081.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc14-S081</ArticleId><ArticleId IdType="pmc">PMC3968448</ArticleId><ArticleId IdType="pubmed">23959568</ArticleId></ArticleIdList></Reference><Reference><Citation>Buse J.B., Caprio S., Cefalu W.T., Ceriello A., Del Prato S., Inzucchi S.E., McLaughlin S., Phillips G.L., 2nd, Robertson R.P., Rubino F., et al. How do we define cure of diabetes? Diabetes Care. 2009;32:2133&#x2013;2135. doi: 10.2337/dc09-9036.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc09-9036</ArticleId><ArticleId IdType="pmc">PMC2768219</ArticleId><ArticleId IdType="pubmed">19875608</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco-Rojo R., Alcala-Diaz J.F., Wopereis S., Perez-Martinez P., Quintana-Navarro G.M., Marin C., Ordovas J.M., van Ommen B., Perez-Jimenez F., Delgado-Lista J., Lopez-Miranda J. The insulin resistance phenotype (muscle or liver) interacts with the type of diet to determine changes in disposition index after 2 years of intervention: the CORDIOPREV-DIAB randomised clinical trial. Diabetologia. 2016;59:67&#x2013;76. doi: 10.1007/s00125-015-3776-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-015-3776-4</ArticleId><ArticleId IdType="pubmed">26474775</ArticleId></ArticleIdList></Reference><Reference><Citation>Roncero-Ramos I., Jimenez-Lucena R., Alcala-Diaz J.F., Vals-Delgado C., Arenas-Larriva A.P., Rangel-Zu&#xf1;iga O.A., Leon-Acu&#xf1;a A., Malagon M.M., Delgado-Lista J., Perez-Martinez P., et al. Alpha cell function interacts with diet to modulate prediabetes and Type 2 diabetes. J.&#xa0;Nutr. Biochem. 2018;62:247&#x2013;256. doi: 10.1016/j.jnutbio.2018.08.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jnutbio.2018.08.012</ArticleId><ArticleId IdType="pubmed">30336335</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuda M., DeFronzo R.A. Insulin Sensitivity Indices Obtained From Oral Glucose Tolerance Testing. Diabetes Care. 1999;22:1462&#x2013;1470. doi: 10.2337/diacare.22.9.1462.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diacare.22.9.1462</ArticleId><ArticleId IdType="pubmed">10480510</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39707172</PMID><DateCompleted><Year>2024</Year><Month>12</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1528-3658</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Dec</Month><Day>20</Day></PubDate></JournalIssue><Title>Molecular medicine (Cambridge, Mass.)</Title><ISOAbbreviation>Mol Med</ISOAbbreviation></Journal><ArticleTitle>Increased expression levels of PIEZO1 in visceral adipose tissue in obesity and type 2 diabetes are triggered by mechanical forces and are associated with inflammation.</ArticleTitle><Pagination><StartPage>255</StartPage><MedlinePgn>255</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">255</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s10020-024-01008-1</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">PIEZO1 has emerged as a mechanoreceptor linked with adipogenesis, adipose tissue (AT) inflammation and insulin resistance. We aimed to determine the impact of obesity and obesity-associated type 2 diabetes (T2D) as well as mechanical compression forces on the expression of PIEZO1 in visceral AT (VAT) and its relation with inflammation.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Blood and VAT&#xa0;samples were obtained from 100 volunteers. Static compression studies in VAT explants were performed to study the PIEZO1 response. The effect of bariatric surgery on the expression of Piezo1 was assessed in a rat model of diet-induced obesity.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Obesity and obesity-associated T2D increased (P&#x2009;&lt;&#x2009;0.01) gene expression levels of PIEZO1 in VAT mainly due to adipocytes. SWELL1 and key markers of inflammation (NLRP3, NLRP6, IL1B, IL18 and IL8) were also upregulated in VAT in obesity and T2D being significantly associated (P&#x2009;&lt;&#x2009;0.01) with PIEZO1 levels. We further showed that the static compression of VAT explants promoted an upregulation of PIEZO1 (P&#x2009;&lt;&#x2009;0.01) and SWELL1 (P&#x2009;&lt;&#x2009;0.01) expression levels together with a strong increase in the expression and release of key inflammatory mediators. The treatment of THP-1-derived macrophages with the secretome of adipocytes from patients with obesity upregulated (P&#x2009;&lt;&#x2009;0.001) PIEZO1 levels. Rats undergoing bariatric surgery exhibited decreased (P&#x2009;&lt;&#x2009;0.01) expression levels of Piezo1 in the epididymal AT.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Static compression triggered an upregulation of PIEZO1 in VAT explants together with a strong inflammation. In addition, the increased expression of PIEZO1 in VAT in obesity and obesity-associated T2D, primarily attributable to adipocytes, is closely associated with SWELL1 and inflammatory markers.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Catal&#xe1;n</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Metabolic Research Laboratory, Cl&#xed;nica Universidad de Navarra, Pamplona, Spain. vcatalan@unav.es.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER Fisiopatolog&#xed;a de la Obesidad y Nutrici&#xf3;n (CIBEROBN), Instituto de Salud Carlos III, Pamplona, Spain. vcatalan@unav.es.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Obesity and Adipobiology Group, Instituto de Investigaci&#xf3;n Sanitaria de Navarra (IdiSNA), Pamplona, Spain. vcatalan@unav.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;mez-Ambrosi</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Metabolic Research Laboratory, Cl&#xed;nica Universidad de Navarra, Pamplona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER Fisiopatolog&#xed;a de la Obesidad y Nutrici&#xf3;n (CIBEROBN), Instituto de Salud Carlos III, Pamplona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Obesity and Adipobiology Group, Instituto de Investigaci&#xf3;n Sanitaria de Navarra (IdiSNA), Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ram&#xed;rez</LastName><ForeName>Beatriz</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Metabolic Research Laboratory, Cl&#xed;nica Universidad de Navarra, Pamplona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER Fisiopatolog&#xed;a de la Obesidad y Nutrici&#xf3;n (CIBEROBN), Instituto de Salud Carlos III, Pamplona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Obesity and Adipobiology Group, Instituto de Investigaci&#xf3;n Sanitaria de Navarra (IdiSNA), Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Unamuno</LastName><ForeName>Xabier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Metabolic Research Laboratory, Cl&#xed;nica Universidad de Navarra, Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Becerril</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Metabolic Research Laboratory, Cl&#xed;nica Universidad de Navarra, Pamplona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER Fisiopatolog&#xed;a de la Obesidad y Nutrici&#xf3;n (CIBEROBN), Instituto de Salud Carlos III, Pamplona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Obesity and Adipobiology Group, Instituto de Investigaci&#xf3;n Sanitaria de Navarra (IdiSNA), Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez</LastName><ForeName>Amaia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Metabolic Research Laboratory, Cl&#xed;nica Universidad de Navarra, Pamplona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER Fisiopatolog&#xed;a de la Obesidad y Nutrici&#xf3;n (CIBEROBN), Instituto de Salud Carlos III, Pamplona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Obesity and Adipobiology Group, Instituto de Investigaci&#xf3;n Sanitaria de Navarra (IdiSNA), Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baixauli</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Surgery, Cl&#xed;nica Universidad de Navarra, Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reina</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Cl&#xed;nica Universidad de Navarra, Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sancho</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Biomedical Engineering and Science Department, University of Navarra, TECNUN School of Engineering, San Sebasti&#xe1;n, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Camilo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>CIBER Fisiopatolog&#xed;a de la Obesidad y Nutrici&#xf3;n (CIBEROBN), Instituto de Salud Carlos III, Pamplona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Endocrinology and Nutrition, Cl&#xed;nica Universidad de Navarra, Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cienfuegos</LastName><ForeName>Javier A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>CIBER Fisiopatolog&#xed;a de la Obesidad y Nutrici&#xf3;n (CIBEROBN), Instituto de Salud Carlos III, Pamplona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Obesity and Adipobiology Group, Instituto de Investigaci&#xf3;n Sanitaria de Navarra (IdiSNA), Pamplona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Cl&#xed;nica Universidad de Navarra, Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fr&#xfc;hbeck</LastName><ForeName>Gema</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Metabolic Research Laboratory, Cl&#xed;nica Universidad de Navarra, Pamplona, Spain. gfruhbeck@unav.es.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER Fisiopatolog&#xed;a de la Obesidad y Nutrici&#xf3;n (CIBEROBN), Instituto de Salud Carlos III, Pamplona, Spain. gfruhbeck@unav.es.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Obesity and Adipobiology Group, Instituto de Investigaci&#xf3;n Sanitaria de Navarra (IdiSNA), Pamplona, Spain. gfruhbeck@unav.es.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Endocrinology and Nutrition, Cl&#xed;nica Universidad de Navarra, Pamplona, Spain. gfruhbeck@unav.es.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>PI23/00208</GrantID><Agency>Instituto de Salud Carlos III</Agency><Country/></Grant><Grant><GrantID>PI22/00745</GrantID><Agency>Instituto de Salud Carlos III</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>12</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Med</MedlineTA><NlmUniqueID>9501023</NlmUniqueID><ISSNLinking>1076-1551</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007473">Ion Channels</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C515204">PIEZO1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007473" MajorTopicYN="Y">Ion Channels</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050152" MajorTopicYN="Y">Intra-Abdominal Fat</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009765" MajorTopicYN="Y">Obesity</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="Y">Inflammation</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050110" MajorTopicYN="N">Bariatric Surgery</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013314" MajorTopicYN="N">Stress, Mechanical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Mechanotransduction</Keyword><Keyword MajorTopicYN="N">Obesity</Keyword><Keyword MajorTopicYN="N">PIEZO1</Keyword><Keyword MajorTopicYN="N">Type 2 diabetes</Keyword><Keyword MajorTopicYN="N">VAT</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: The protocol of the research was conformed to the guidelines of the Declaration of Helsinki and was approved by the Universidad de Navarra&#x2019;s Ethical Committee (protocol 2020.054). The animal procedures followed the European Guidelines for the Care and Use of Laboratory Animals (directive 2010/63/EU) and were approved by the Ethical Committee for Animal Experimentation of the University of Navarra (2019.089). Informed consent was obtained from all individual participants included in the study. Consent of publication: Not applicable. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>21</Day><Hour>16</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>21</Day><Hour>16</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>20</Day><Hour>23</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>12</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39707172</ArticleId><ArticleId IdType="pmc">PMC11660983</ArticleId><ArticleId IdType="doi">10.1186/s10020-024-01008-1</ArticleId><ArticleId IdType="pii">10.1186/s10020-024-01008-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alkhouli N, Mansfield J, Green E, Bell J, Knight B, Liversedge N, et al. The mechanical properties of human adipose tissues and their relationships to the structure and composition of the extracellular matrix. Am J Physiol Endocrinol Metab. 2013;305:E1427-1435.</Citation><ArticleIdList><ArticleId IdType="pubmed">24105412</ArticleId></ArticleIdList></Reference><Reference><Citation>Atcha H, Jairaman A, Holt JR, Meli VS, Nagalla RR, Veerasubramanian PK, et al. Mechanically activated ion channel Piezo1 modulates macrophage polarization and stiffness sensing. Nat Commun. 2021;12:3256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8167181</ArticleId><ArticleId IdType="pubmed">34059671</ArticleId></ArticleIdList></Reference><Reference><Citation>Baxter EW, Graham AE, Re NA, Carr IM, Robinson JI, Mackie SL, et al. Standardized protocols for differentiation of THP-1 cells to macrophages with distinct M(IFNg+LPS), M(IL-4) and M(IL-10) phenotypes. J Immunol Methods. 2020;478: 112721.</Citation><ArticleIdList><ArticleId IdType="pubmed">32033786</ArticleId></ArticleIdList></Reference><Reference><Citation>Becerril S, Cienfuegos JA, Rodriguez A, Catalan V, Ramirez B, Valenti V, et al. Single anastomosis duodeno-ileal bypass with sleeve gastrectomy generates sustained improvement of glycemic control compared with sleeve gastrectomy in the diet-induced obese rat model. J Physiol Biochem. 2024;80:149&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10810039</ArticleId><ArticleId IdType="pubmed">37935948</ArticleId></ArticleIdList></Reference><Reference><Citation>Blade SP, Falkowski DJ, Bachand SN, Pagano SJ, Chin L. Mechanobiology of adipocytes. Biology. 2024;13:434.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11200640</ArticleId><ArticleId IdType="pubmed">38927314</ArticleId></ArticleIdList></Reference><Reference><Citation>Coste B, Mathur J, Schmidt M, Earley TJ, Ranade S, Petrus MJ, et al. Piezo1 and Piezo2 are essential components of distinct mechanically activated cation channels. Science. 2010;330:55&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3062430</ArticleId><ArticleId IdType="pubmed">20813920</ArticleId></ArticleIdList></Reference><Reference><Citation>Deivasikamani V, Dhayalan S, Abudushalamu Y, Mughal R, Visnagri A, Cuthbertson K, et al. Piezo1 channel activation mimics high glucose as a stimulator of insulin release. Sci Rep. 2019;9:16876.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6856185</ArticleId><ArticleId IdType="pubmed">31727906</ArticleId></ArticleIdList></Reference><Reference><Citation>Diem K, Fauler M, Fois G, Hellmann A, Winokurow N, Schumacher S, et al. Mechanical stretch activates piezo1 in caveolae of alveolar type I cells to trigger ATP release and paracrine stimulation of surfactant secretion from alveolar type II cells. FASEB J. 2020;34:12785&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pubmed">32744386</ArticleId></ArticleIdList></Reference><Reference><Citation>Fish A, Kulkarni A. Flow-induced shear stress primes NLRP3 inflammasome activation in macrophages via Piezo1. ACS Appl Mater Interfaces. 2024;16:4505&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">38240257</ArticleId></ArticleIdList></Reference><Reference><Citation>Fr&#xfc;hbeck G, G&#xf3;mez-Ambrosi J, Salvador J. Leptin-induced lipolysis opposes the tonic inhibition of endogenous adenosine in white adipocytes. FASEB J. 2001;15:333&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">11156949</ArticleId></ArticleIdList></Reference><Reference><Citation>Fr&#xfc;hbeck G, L&#xf3;pez M, Dieguez C. Role of caveolins in body weight and insulin resistance regulation. Trends Endocrinol Metab. 2007;18:177&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">17433707</ArticleId></ArticleIdList></Reference><Reference><Citation>Fr&#xfc;hbeck G, G&#xf3;mez-Ambrosi J, Ram&#xed;rez B, Mentxaka A, Rodr&#xed;guez A, Becerril S, et al. Increased levels of interleukin-36 in obesity and type 2 diabetes fuel adipose tissue inflammation by inducing its own expression and release by adipocytes and macrophages. Front Immunol. 2022;13: 832185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8863603</ArticleId><ArticleId IdType="pubmed">35222417</ArticleId></ArticleIdList></Reference><Reference><Citation>Geng J, Shi Y, Zhang J, Yang B, Wang P, Yuan W, et al. TLR4 signalling via Piezo1 engages and enhances the macrophage mediated host response during bacterial infection. Nat Commun. 2021;12:3519.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8192512</ArticleId><ArticleId IdType="pubmed">34112781</ArticleId></ArticleIdList></Reference><Reference><Citation>Gliniak CM, Pedersen L, Scherer PE. Adipose tissue fibrosis: the unwanted houseguest invited by obesity. J Endocrinol. 2023;259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11648981</ArticleId><ArticleId IdType="pubmed">37855264</ArticleId></ArticleIdList></Reference><Reference><Citation>Gnanasambandam R, Bae C, Gottlieb PA, Sachs F. Ionic selectivity and permeation properties of human PIEZO1 channels. PLoS ONE. 2015;10: e0125503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4425559</ArticleId><ArticleId IdType="pubmed">25955826</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Ambrosi J, Salvador J, Rotellar F, Silva C, Catal&#xe1;n V, Rodr&#xed;guez A, et al. Increased serum amyloid A concentrations in morbid obesity decrease after gastric bypass. Obes Surg. 2006;16:262&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16545156</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong T, Yang Y, Jin T, Jiang W, Zhou R. Orchestration of NLRP3 inflammasome activation by ion fluxes. Trends Immunol. 2018;39:393&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">29452983</ArticleId></ArticleIdList></Reference><Reference><Citation>Gudipaty SA, Lindblom J, Loftus PD, Redd MJ, Edes K, Davey CF, et al. Mechanical stretch triggers rapid epithelial cell division through Piezo1. Nature. 2017;543:118&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5334365</ArticleId><ArticleId IdType="pubmed">28199303</ArticleId></ArticleIdList></Reference><Reference><Citation>Haselwandter CA, MacKinnon R. Piezo's membrane footprint and its contribution to mechanosensitivity. Elife 2018;7:e41968</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6317911</ArticleId><ArticleId IdType="pubmed">30480546</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinonen S, Saarinen L, Naukkarinen J, Rodriguez A, Fruhbeck G, Hakkarainen A, et al. Adipocyte morphology and implications for metabolic derangements in acquired obesity. Int J Obes (Lond). 2014;38:1423&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">24549139</ArticleId></ArticleIdList></Reference><Reference><Citation>Humphrey JD, Dufresne ER, Schwartz MA. Mechanotransduction and extracellular matrix homeostasis. Nat Rev Mol Cell Biol. 2014;15:802&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4513363</ArticleId><ArticleId IdType="pubmed">25355505</ArticleId></ArticleIdList></Reference><Reference><Citation>Iskratsch T, Wolfenson H, Sheetz MP. Appreciating force and shape-the rise of mechanotransduction in cell biology. Nat Rev Mol Cell Biol. 2014;15:825&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9339222</ArticleId><ArticleId IdType="pubmed">25355507</ArticleId></ArticleIdList></Reference><Reference><Citation>Janmey PA, Fletcher DA, Reinhart-King CA. Stiffness sensing by cells. Physiol Rev. 2020;100:695&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7276923</ArticleId><ArticleId IdType="pubmed">31751165</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee GS, Subramanian N, Kim AI, Aksentijevich I, Goldbach-Mansky R, Sacks DB, et al. The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2+ and cAMP. Nature. 2012;492:123&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4175565</ArticleId><ArticleId IdType="pubmed">23143333</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang F, Kume S, Koya D. SIRT1 and insulin resistance. Nat Rev Endocrinol. 2009;5:367&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">19455179</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Hu J, Zheng Q, Feng X, Zhan F, Wang X, et al. Piezo1 channels as force sensors in mechanical force-related chronic inflammation. Front Immunol. 2022;13: 816149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8826255</ArticleId><ArticleId IdType="pubmed">35154133</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Wang D, Yang X, Ma F, Han W, Hu J, et al. The mechanosensitive ion channel PIEZO1 in intestinal epithelial cells mediates inflammation through the NOD-like receptor 3 pathway in Crohn&#x2019;s disease. Inflamm Bowel Dis. 2023;29:103&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">35907203</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinac B. Mechanosensitive ion channels: molecules of mechanotransduction. J Cell Sci. 2004;117:2449&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">15159450</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinac B, Poole K. Mechanically activated ion channels. Int J Biochem Cell Biol. 2018;97:104&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">29471041</ArticleId></ArticleIdList></Reference><Reference><Citation>McVicker BL, Bennett RG. Novel anti-fibrotic therapies. Front Pharmacol. 2017;8:318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5449464</ArticleId><ArticleId IdType="pubmed">28620300</ArticleId></ArticleIdList></Reference><Reference><Citation>Min S, Oh Y, Verma P, Whitehead SC, Yapici N, Van Vactor D, et al. Control of feeding by Piezo-mediated gut mechanosensation in Drosophila. Elife. 2021;10:e63049.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7920550</ArticleId><ArticleId IdType="pubmed">33599608</ArticleId></ArticleIdList></Reference><Reference><Citation>Murthy SE, Dubin AE, Patapoutian A. Piezos thrive under pressure: mechanically activated ion channels in health and disease. Nat Rev Mol Cell Biol. 2017;18:771&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">28974772</ArticleId></ArticleIdList></Reference><Reference><Citation>Portincasa P, Fr&#xfc;hbeck G. Phenotyping the obesities: reality or utopia? Rev Endocr Metab Disord. 2023;24:767&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10492876</ArticleId><ArticleId IdType="pubmed">37537402</ArticleId></ArticleIdList></Reference><Reference><Citation>American Diabetes Association Professional Practice C. Diagnosis and classification of diabetes: standards of care in diabetes-2024. Diabetes Care. 2024;47: S20&#x2013;S42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10725812</ArticleId><ArticleId IdType="pubmed">38078589</ArticleId></ArticleIdList></Reference><Reference><Citation>Ran L, Ye T, Erbs E, Ehl S, Spassky N, Sumara I, et al. KCNN4 links PIEZO-dependent mechanotransduction to NLRP3 inflammasome activation. Sci Immunol. 2023;8: eadf4699.</Citation><ArticleIdList><ArticleId IdType="pubmed">38134241</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridone P, Vassalli M, Martinac B. Piezo1 mechanosensitive channels: what are they and why are they important. Biophys Rev. 2019;11:795&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6815293</ArticleId><ArticleId IdType="pubmed">31494839</ArticleId></ArticleIdList></Reference><Reference><Citation>Romani P, Valcarcel-Jimenez L, Frezza C, Dupont S. Crosstalk between mechanotransduction and metabolism. Nat Rev Mol Cell Biol. 2021;22:22&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">33188273</ArticleId></ArticleIdList></Reference><Reference><Citation>Sell H, Habich C, Eckel J. Adaptive immunity in obesity and insulin resistance. Nat Rev Endocrinol. 2012;8:709&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">22847239</ArticleId></ArticleIdList></Reference><Reference><Citation>Solis AG, Bielecki P, Steach HR, Sharma L, Harman CCD, Yun S, et al. Mechanosensation of cyclical force by PIEZO1 is essential for innate immunity. Nature. 2019;573:69&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6939392</ArticleId><ArticleId IdType="pubmed">31435009</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Leng P, Song M, Li D, Guo P, Xu X, et al. Piezo1 activates the NLRP3 inflammasome in nucleus pulposus cell-mediated by Ca2+/NF-&#x3ba;B pathway. Int Immunopharmacol. 2020;85: 106681.</Citation><ArticleIdList><ArticleId IdType="pubmed">32526681</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun K, Li X, Scherer PE. Extracellular matrix (ECM) and fibrosis in adipose tissue: overview and perspectives. Compr Physiol. 2023;13:4387&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9957663</ArticleId><ArticleId IdType="pubmed">36715281</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Y, Zhao C, Zhuang Y, Zhong A, Wang M, Zhang W, et al. Mechanosensitive Piezo1 protein as a novel regulator in macrophages and macrophage-mediated inflammatory diseases. Front Immunol. 2023;14:1149336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10275567</ArticleId><ArticleId IdType="pubmed">37334369</ArticleId></ArticleIdList></Reference><Reference><Citation>Thalmann S, Juge-Aubry CE, Meier CA. Explant cultures of white adipose tissue. Methods Mol Biol. 2008;456:195&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">18516562</ArticleId></ArticleIdList></Reference><Reference><Citation>Unamuno X, G&#xf3;mez-Ambrosi J, Rodr&#xed;guez A, Becerril S, Fr&#xfc;hbeck G, Catal&#xe1;n V. Adipokine dysregulation and adipose tissue inflammation in human obesity. Eur J Clin Invest. 2018;48: e12997.</Citation><ArticleIdList><ArticleId IdType="pubmed">29995306</ArticleId></ArticleIdList></Reference><Reference><Citation>Unamuno X, G&#xf3;mez-Ambrosi J, Ram&#xed;rez B, Rodr&#xed;guez A, Becerril S, Valent&#xed; V, et al. NLRP3 inflammasome blockade reduces adipose tissue inflammation and extracellular matrix remodeling. Cell Mol Immunol. 2021;18:1045&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8115140</ArticleId><ArticleId IdType="pubmed">31551515</ArticleId></ArticleIdList></Reference><Reference><Citation>Unamuno X, G&#xf3;mez-Ambrosi J, Becerril S, &#xc1;lvarez-Cienfuegos FJ, Ram&#xed;rez B, Rodr&#xed;guez A, et al. Changes in mechanical properties of adipose tissue after bariatric surgery driven by extracellular matrix remodelling and neovascularization are associated with metabolic improvements. Acta Biomater. 2022;141:264&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">35007786</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Cao S, Arhatte M, Li D, Shi Y, Kurz S, et al. Adipocyte Piezo1 mediates obesogenic adipogenesis through the FGF1/FGFR1 signaling pathway in mice. Nat Commun. 2020;11:2303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7211025</ArticleId><ArticleId IdType="pubmed">32385276</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Zhang Z, Yang Q, Cao Y, Dong Y, Bi Y, et al. Immunoregulatory role of the mechanosensitive ion channel Piezo1 in inflammation and cancer. Molecules. 2022;28:213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9822220</ArticleId><ArticleId IdType="pubmed">36615408</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112:1796&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC296995</ArticleId><ArticleId IdType="pubmed">14679176</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie L, Zhang Y, Gunasekar SK, Mishra A, Cao L, Sah R. Induction of adipose and hepatic SWELL1 expression is required for maintaining systemic insulin-sensitivity in obesity. Channels (Austin). 2017;11:673&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5786185</ArticleId><ArticleId IdType="pubmed">28873008</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye Y, Barghouth M, Dou H, Luan C, Wang Y, Karagiannopoulos A, et al. A critical role of the mechanosensor PIEZO1 in glucose-induced insulin secretion in pancreatic beta-cells. Nat Commun. 2022;13:4237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9307633</ArticleId><ArticleId IdType="pubmed">35869052</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Xie L, Gunasekar SK, Tong D, Mishra A, Gibson WJ, et al. SWELL1 is a regulator of adipocyte size, insulin signalling and glucose homeostasis. Nat Cell Biol. 2017;19:504&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5415409</ArticleId><ArticleId IdType="pubmed">28436964</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao C, Sun Q, Tang L, Cao Y, Nourse JL, Pathak MM, et al. Mechanosensitive ion channel Piezo1 regulates diet-induced adipose inflammation and systemic insulin resistance. Front Endocrinol. 2019;10:373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6584899</ArticleId><ArticleId IdType="pubmed">31263454</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Liu Y, Tao T, Zhang J, Guo W, Deng H, et al. Gastric mechanosensitive channel Piezo1 regulates ghrelin production and food intake. Nat Metab. 2024;6:458&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">38467889</ArticleId></ArticleIdList></Reference><Reference><Citation>Zong B, Yu F, Zhang X, Pang Y, Zhao W, Sun P, et al. Mechanosensitive Piezo1 channel in physiology and pathophysiology of the central nervous system. Ageing Res Rev. 2023;90: 102026.</Citation><ArticleIdList><ArticleId IdType="pubmed">37532007</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39466646</PMID><DateCompleted><Year>2025</Year><Month>04</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2769-707X</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>3</Issue><PubDate><Year>2025</Year><Season>Mar-Apr</Season></PubDate></JournalIssue><Title>Journal of the American Nutrition Association</Title><ISOAbbreviation>J Am Nutr Assoc</ISOAbbreviation></Journal><ArticleTitle>Adherence to a Healthful Plant-Based Diet and Risk of Chronic Kidney Disease Among Individuals with Diabetes.</ArticleTitle><Pagination><StartPage>212</StartPage><EndPage>222</EndPage><MedlinePgn>212-222</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/27697061.2024.2415917</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">Chronic kidney disease (CKD) is highly prevalent among people with diabetes. While identifying modifiable risk factors to prevent a decline in kidney function among those living with diabetes is pivotal, there is limited evidence on dietary risk factors for CKD. In this study, we examined the associations between healthy and less healthy plant-based diets (PBDs) and the risk of CKD among those with diabetes, and to identify potential underlying mechanisms.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We conducted a prospective analysis among 7,747 UK Biobank participants with prevalent diabetes. Multivariable Cox proportional hazard regression models were used to examine the associations between healthful and unhealthful PBDs and the risk of CKD. Causal mediation analyses were further employed to explore the underlying mechanisms of the observed associations.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Among 7,747 study participants with diabetes, 1,030 developed incident CKD over 10.2&#x2009;years of follow-up. Higher adherence to a healthy PBD was associated with a 24% lower CKD risk (HR<sub>Q4 versus Q1</sub>: 0.76 [95%CI: 0.63-0.92], <i>p</i><sub>trend</sub> = 0.002), while higher adherence to an unhealthy PBD was associated with a 35% higher risk (HR<sub>Q4 versus Q1</sub>: 1.35 [95%CI: 1.11-1.65], <i>p</i><sub>trend</sub> = 0.006). The observed associations were predominantly mediated by markers of body fatness (proportion mediated: 11-25%) and kidney function (23-89%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">In this prospective cohort study of middle-aged adults with diabetes, adherence to a healthy PBD was associated with lower CKD risk, whereas adherence to an unhealthy PBD was associated with a higher CKD risk. Associations were primarily mediated by markers of lower body fatness and improved kidney function.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Alysha S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>The Co-Centre for Sustainable Food Systems and The Institute for Global Food Security, School of Biological Sciences, Queen's University Belfast, Belfast, Northern Ireland, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tresserra-Rimbau</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Co-Centre for Sustainable Food Systems and The Institute for Global Food Security, School of Biological Sciences, Queen's University Belfast, Belfast, Northern Ireland, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nutrition, Food Science and Gastronomy, XIA, School of Pharmacy and Food Sciences, INSA, University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Fisiopatolog&#xed;a de la Obesidad y la Nutrici&#xf3;n (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jennings</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Co-Centre for Sustainable Food Systems and The Institute for Global Food Security, School of Biological Sciences, Queen's University Belfast, Belfast, Northern Ireland, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bondonno</LastName><ForeName>Nicola P</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>The Co-Centre for Sustainable Food Systems and The Institute for Global Food Security, School of Biological Sciences, Queen's University Belfast, Belfast, Northern Ireland, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Danish Cancer Institute, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nutrition &amp; Health Innovation Research Institute, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Candussi</LastName><ForeName>Catharina J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Nutritional Sciences, University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Public Health, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Neill</LastName><ForeName>Joshua K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>The Co-Centre for Sustainable Food Systems and The Institute for Global Food Security, School of Biological Sciences, Queen's University Belfast, Belfast, Northern Ireland, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centre for Public Health, Queen's University Belfast, Belfast, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaggl</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Public Health, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cassidy</LastName><ForeName>Aed&#xed;n</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0048-5602</Identifier><AffiliationInfo><Affiliation>The Co-Centre for Sustainable Food Systems and The Institute for Global Food Security, School of Biological Sciences, Queen's University Belfast, Belfast, Northern Ireland, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xfc;hn</LastName><ForeName>Tilman</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-7702-317X</Identifier><AffiliationInfo><Affiliation>The Co-Centre for Sustainable Food Systems and The Institute for Global Food Security, School of Biological Sciences, Queen's University Belfast, Belfast, Northern Ireland, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nutritional Sciences, University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Public Health, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Nutr Assoc</MedlineTA><NlmUniqueID>9918300687506676</NlmUniqueID><ISSNLinking>2769-7061</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051436" MajorTopicYN="Y">Renal Insufficiency, Chronic</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014676" MajorTopicYN="Y">Diet, Vegetarian</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072001" MajorTopicYN="Y">Diet, Healthy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003920" MajorTopicYN="Y">Diabetes Mellitus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010349" MajorTopicYN="Y">Patient Compliance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000095500" MajorTopicYN="N">Diet, Plant-Based</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Plant-based diet index</Keyword><Keyword MajorTopicYN="N">chronic kidney disease</Keyword><Keyword MajorTopicYN="N">diabetes mellitus</Keyword><Keyword MajorTopicYN="N">mediation analysis</Keyword><Keyword MajorTopicYN="N">primary prevention</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>5</Day><Hour>18</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>18</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>12</Hour><Minute>34</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39466646</ArticleId><ArticleId IdType="doi">10.1080/27697061.2024.2415917</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39045915</PMID><DateCompleted><Year>2024</Year><Month>07</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1809-4546</ISSN><JournalIssue CitedMedium="Internet"><Volume>51</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Revista do Colegio Brasileiro de Cirurgioes</Title><ISOAbbreviation>Rev Col Bras Cir</ISOAbbreviation></Journal><ArticleTitle>Clinical-epidemiological assessment of patients undergoing bariatric and metabolic surgery in a medium-complexity service in Maranh&#xe3;o, Brazil.</ArticleTitle><Pagination><StartPage>e20243708</StartPage><MedlinePgn>e20243708</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e20243708</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1590/0100-6991e-20243708-en</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0100-69912024000100214</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">the obesity is defined as the excessive accumulation of fat in different areas of the body, a condition that causes damage to health and is a critical risk factor for various comorbidities. Bariatric surgery is the therapeutic option with the best results.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">this is a retrospective descriptive study using data obtained from medical records from January 2018 to December 2020 on patients undergoing bariatric surgery. Statistical analysis used a significance level of p&lt;0.05.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">178 medical records were included, 77.5% of which were women. The average age was 35.7 years (&#xb1; 9.5), 63.8% of the patients were from Imperatriz, 98.3% reported a sedentary lifestyle, 38.7% regular alcohol consumption and 13% smoking. The prevalence of Class III obesity (BMI&#x2265;40 kg/m&#xb2;) was 53.3%. The most common comorbidities were hepatic steatosis (64.6%), type 2 diabetes mellitus (DM2) (40.5%) and hypertension (38.7%). The main type of surgery performed was Roux-en-Y gastric bypass (RYGB) (89.3%). There was an association between median BMI and gender (p=0.008), with women showing higher values [43.4 (IQR 39.1 - 48.8)]. The mean BMI of patients who underwent RYGB was significantly higher compared to those who underwent vertical gastrectomy (VG) (p=0.009). There was a statistical association between DM2 (p=0.033) and depression (p=0.018) and the type of surgery performed.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">the clinical and epidemiological profile found showed a higher prevalence of females and individuals with Class III obesity. RYGB was the most commonly performed procedure, establishing an association with BMI and some of the patients' comorbidities.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barbosa</LastName><ForeName>Livio Melo</ForeName><Initials>LM</Initials><Identifier Source="ORCID">0000-0002-5059-4535</Identifier><AffiliationInfo><Affiliation>- Universidade Federal do Maranh&#xe3;o, Curso de Medicina - Centro de Ci&#xea;ncias de Imperatriz - Imperatriz - MA - Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sirqueira</LastName><ForeName>Bruna Pereira Carvalho</ForeName><Initials>BPC</Initials><Identifier Source="ORCID">0000-0002-6434-8546</Identifier><AffiliationInfo><Affiliation>- Universidade Federal do Maranh&#xe3;o, Curso de Medicina - Centro de Ci&#xea;ncias de Imperatriz - Imperatriz - MA - Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carvalho</LastName><ForeName>Jos&#xe9; Thiago Oliveira DE</ForeName><Initials>JTO</Initials><Identifier Source="ORCID">0009-0000-2094-5034</Identifier><AffiliationInfo><Affiliation>- Universidade Federal do Maranh&#xe3;o, Curso de Medicina - Centro de Ci&#xea;ncias de Imperatriz - Imperatriz - MA - Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barros</LastName><ForeName>Alberto N&#xe9;lio Bandeira</ForeName><Initials>ANB</Initials><Identifier Source="ORCID">0009-0002-5540-2659</Identifier><AffiliationInfo><Affiliation>- Cl&#xed;nica de Sa&#xfa;de Nutrogastro - Centro De Cirurgia Geral, Digestiva e Obesidade - Imperatriz - MA - Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lima</LastName><ForeName>Anderson Bentes DE</ForeName><Initials>AB</Initials><Identifier Source="ORCID">0009-0003-7187-9198</Identifier><AffiliationInfo><Affiliation>- Universidade Estadual do Par&#xe1; - Programa de Mestrado Profissional em Cirurgia e Pesquisa Experimental - Centro de Ci&#xea;ncias da Sa&#xfa;de - Bel&#xe9;m - PA - Brasil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>por</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Rev Col Bras Cir</MedlineTA><NlmUniqueID>7809515</NlmUniqueID><ISSNLinking>0100-6991</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001938" MajorTopicYN="N" Type="Geographic">Brazil</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050110" MajorTopicYN="Y">Bariatric Surgery</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009767" MajorTopicYN="N">Obesity, Morbid</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015992" MajorTopicYN="N">Body Mass Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="por"><AbstractText Label="INTRODU&#xc7;&#xc3;O:">a obesidade &#xe9; definida pelo ac&#xfa;mulo excessivo de gordura em diferentes regi&#xf5;es corporais, condi&#xe7;&#xe3;o que acarreta preju&#xed;zos &#xe0; sa&#xfa;de e constitui fator de risco para diversas comorbidades. A cirurgia bari&#xe1;trica &#xe9; a op&#xe7;&#xe3;o terap&#xea;utica com melhores resultados para o seu tratamento.</AbstractText><AbstractText Label="M&#xc9;TODOS:">estudo retrospectivo descritivo realizado com dados obtidos de prontu&#xe1;rios m&#xe9;dicos do per&#xed;odo de janeiro/2018 a dezembro/2020, relacionados a pacientes submetidos &#xe0; cirurgia bari&#xe1;trica. As an&#xe1;lises estat&#xed;sticas realizadas adotaram n&#xed;vel de signific&#xe2;ncia p&lt;0,05.</AbstractText><AbstractText Label="RESULTADOS:">foram inclu&#xed;dos 178 prontu&#xe1;rios, sendo 77,5% de mulheres. A m&#xe9;dia de idade foi de 35,7 anos (&#xb1; 9,5), 63,8% dos pacientes eram procedentes de Imperatriz, 98,3% relataram sedentarismo, 38,7% consumo regular de &#xe1;lcool e 13% tabagismo. A preval&#xea;ncia de obesidade grau III (IMC&#x2265;40 kg/m&#xb2;) foi de 53,3%. As comorbidades mais relacionadas foram esteatose hep&#xe1;tica (64,6%), diabetes mellitus tipo 2 (DM2) (40,5%) e hipertens&#xe3;o arterial (38,7%). O principal tipo de cirurgia realizada foi o by-pass g&#xe1;strico em Y de Roux (BGYR) (89,3%). Observou-se associa&#xe7;&#xe3;o entre a mediana de IMC e o sexo (p=0,008), com as mulheres apresentando maiores valores [43,4 (IIQ 39,1 - 48,8)]. A m&#xe9;dia de IMC dos pacientes submetidos ao BGYR foi significativamente maior comparado aos que realizaram gastrectomia vertical (GV) (p=0,009). Houve associa&#xe7;&#xe3;o estat&#xed;stica entre o DM2 (p=0,033) e a depress&#xe3;o (p=0,018) com o tipo de cirurgia realizada.</AbstractText><AbstractText Label="CONCLUS&#xc3;O:">o perfil cl&#xed;nico-epidemiol&#xf3;gico encontrado evidenciou maior preval&#xea;ncia do sexo feminino e de indiv&#xed;duos com obesidade grau III. O BGYR foi o procedimento mais realizado, estabelecendo associa&#xe7;&#xe3;o com IMC e algumas comorbidades apresentadas pelos pacientes.</AbstractText></OtherAbstract><CoiStatement>Conflict of interest: no.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>24</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>24</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>24</Day><Hour>7</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39045915</ArticleId><ArticleId IdType="pmc">PMC11449510</ArticleId><ArticleId IdType="doi">10.1590/0100-6991e-20243708-en</ArticleId><ArticleId IdType="pii">S0100-69912024000100214</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Park S, Lee S, Kim Y, Lee Y, Kang MW, Han K. Altered risk for cardiovascular events with changes in the metabolic syndrome status a Nationwide population-based study of approximately 10 million persons. Ann Intern Med. 2019;171(12):875&#x2013;884. doi: 10.7326/M19-0563.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M19-0563</ArticleId><ArticleId IdType="pubmed">31766057</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacerda RMR, Castanha CR, Castanha AR, Campos JM, Ferraz &#xc1;AB, Vilar L. Perception of body image by patients undergoing bariatric surgery. Rev Col Bras Cir. 2018;45(2):1&#x2013;8. doi: 10.1590/0100-6991e-20181793.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/0100-6991e-20181793</ArticleId><ArticleId IdType="pubmed">29846462</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira AP de S, Szwarcwald CL, Damacena GN. Preval&#xea;ncia e fatores associados da obesidade na popula&#xe7;&#xe3;o brasileira: estudo com dados aferidos da Pesquisa Nacional de Sa&#xfa;de, 2013. Rev Bras Epidemiol. 2013 doi: 10.1590/1980-549720190024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/1980-549720190024</ArticleId><ArticleId IdType="pubmed">30942330</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho AS, Rosa RDS. Cirurgias bari&#xe1;tricas realizadas pelo Sistema &#xda;nico de Sa&#xfa;de em residentes da Regi&#xe3;o Metropolitana de Porto Alegre, Rio Grande do Sul, 2010-2016. Epidemiol Serv Saude. 2018;27(2):1&#x2013;10. doi: 10.5123/S1679-49742018000200008.</Citation><ArticleIdList><ArticleId IdType="doi">10.5123/S1679-49742018000200008</ArticleId><ArticleId IdType="pubmed">29898163</ArticleId></ArticleIdList></Reference><Reference><Citation>IBGE . Pesquisa nacional de sa&#xfa;de 2019: aten&#xe7;&#xe3;o prim&#xe1;ria &#xe0; sa&#xfa;de e informa&#xe7;&#xf5;es antropom&#xe9;tricas. Brasil / IBGE, Coordena&#xe7;&#xe3;o de Trabalho e Rendimento, DF: Minist&#xe9;rio da Sa&#xfa;de; 2020.</Citation></Reference><Reference><Citation>Ruban A, Stoenchev K, Ashrafian H, Teare J. Current treatments for obesity. Clin Med (Northfield Il) 2019;19(3):205&#x2013;212. doi: 10.7861/clinmedicine.19-3-205.</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmedicine.19-3-205</ArticleId><ArticleId IdType="pmc">PMC6542229</ArticleId><ArticleId IdType="pubmed">31092512</ArticleId></ArticleIdList></Reference><Reference><Citation>Schauer PR, Kashyap SR, Wolshu K, Brethayer SA, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2015:687&#x2013;696. doi: 10.1056/NEJMoa1200225..</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1200225.</ArticleId><ArticleId IdType="pmc">PMC3372918</ArticleId><ArticleId IdType="pubmed">22449319</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoub JAS, Alonso PA, Guimar&#xe3;es LMV. Effects of bariatric surgery on the metabolic syndrome. Arq Bras Cir Dig. 2011;24(2):140&#x2013;143. doi: 10.1590/S0102-67202011000200010..</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/S0102-67202011000200010.</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe BM, Kvach E, Eckel RH. Treatment of Obesity Weight Loss and Bariatric Surgery. Circ Res. 2016;118(11):1844&#x2013;1855. doi: 10.1161/CIRCRESAHA.116.307591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.116.307591</ArticleId><ArticleId IdType="pmc">PMC4888907</ArticleId><ArticleId IdType="pubmed">27230645</ArticleId></ArticleIdList></Reference><Reference><Citation>Barros F, Negr&#xe3;o MG, Negr&#xe3;o GG. Compara&#xe7;&#xe3;o da perda de peso ap&#xf3;s sleeve e bypass g&#xe1;strico em Y de Roux Revis&#xe3;o Sistem&#xe1;tica. Arq Bras Cir Dig. 2019;32(4):8&#x2013;11. doi: 10.1590/0102-672020190001e1474.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/0102-672020190001e1474</ArticleId><ArticleId IdType="pmc">PMC6918768</ArticleId><ArticleId IdType="pubmed">31859927</ArticleId></ArticleIdList></Reference><Reference><Citation>Arterburn DE, Courcoulas AP. Bariatric surgery for obesity and metabolic conditions in adults. BMJ. 2014;349:1&#x2013;11. doi: 10.1136/bmj.g3961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.g3961</ArticleId><ArticleId IdType="pmc">PMC4707708</ArticleId><ArticleId IdType="pubmed">25164369</ArticleId></ArticleIdList></Reference><Reference><Citation>SBCBM divulga n&#xfa;meros e pede participa&#xe7;&#xe3;o popular para cobertura da cirurgia metabolica pelos planos de saude. Sociedade Brasileira de Cirurgia Bari&#xe1;trica e Metab&#xf3;lica; 2020.</Citation></Reference><Reference><Citation>Brasil M da S. Portaria no 492, de 31 de Agosto de 2007. Di&#xe1;rio Oficial da Uni&#xe3;o; 2022. pp. 1&#x2013;30.</Citation></Reference><Reference><Citation>Ribeiro GANA, Giapietro HB, Belarmino LB, Salgado-Junior W. Depress&#xe3;o, Ansiedade E Compuls&#xe3;o Alimentar Antes E Ap&#xf3;s Cirurgia Bari&#xe1;trica Problemas Que Persistem. Arq Bras Cir Dig. 2018;31(1):e1356. doi: 10.1590/0102-672020180001e1356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/0102-672020180001e1356</ArticleId><ArticleId IdType="pmc">PMC6050001</ArticleId><ArticleId IdType="pubmed">29947690</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes ACS, Reyes ANL, Menezes MC, Santos LC, C&#xe9;sar CC. Fatores associados ao excesso de peso entre mulheres. Esc Anna Nery. 2012;16(3):451&#x2013;458. doi: 10.1590/S1414-81452012000300004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/S1414-81452012000300004</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida SS, Zanatta DP, Rezende FF. Imagem corporal, ansiedade e depress&#xe3;o em pacientes obesos submetidos &#xe0; cirurgia bari&#xe1;trica. Estud Psicol. 2012;17(1):153&#x2013;160. doi: 10.1590/S1413-294X2012000100019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/S1413-294X2012000100019</ArticleId></ArticleIdList></Reference><Reference><Citation>Palheta R, Costa V, Br&#xed;gida E, Dias J, Nogueira A, Figueira M. Avalia&#xe7;&#xe3;o da perda de peso e comorbidades em pacientes submetido &#xe0; cirurgia bari&#xe1;trica em uma cl&#xed;nica particular em Bel&#xe9;m-PA. RBONE - Rev Bras Obesidade, Nutr e Emagrecimento. 2017;11(65):281&#x2013;289.</Citation></Reference><Reference><Citation>Junges VM, Cavalheiro JMB, Fam EF, Closs VE, Gottlieb MGV. Perfil do paciente obeso e portador de s&#xed;ndrome metab&#xf3;lica candidato &#xe0; cirurgia bari&#xe1;trica em uma cl&#xed;nica particular de Porto Alegre, Rio Grande do Sul. Sci Med (Porto Alegre) 2016;26(3) doi: 10.15448/1980-6108.2016.3.22898..</Citation><ArticleIdList><ArticleId IdType="doi">10.15448/1980-6108.2016.3.22898.</ArticleId></ArticleIdList></Reference><Reference><Citation>Brasil M da S.  Vigitel Brasil 2018: Vigil&#xe2;ncia de fatores de risco e prote&#xe7;&#xe3;o para doen&#xe7;as cr&#xf4;nicas por inquerito telef&#xf4;nico [Internet] G. Estat&#xed;stica e Informa&#xe7;&#xe3;o em Sa&#xfa;de; 2019. 131. http://bvsms.saude.gov.br/bvs/publicacoes/vigitel_brasil_2011_fatores_risco_doencas_cronicas.pdf</Citation></Reference><Reference><Citation>Flack KD, Ufholz K, Johnson L, Fitzgerald JS, Roemmich JN. Energy compensation in response to aerobic exercise training in overweight adults. Am J Physiol - Regul Integr Comp Physiol. 2018;315(4):R619&#x2013;R626. doi: 10.1152/ajpregu.00071.2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpregu.00071.2018</ArticleId><ArticleId IdType="pmc">PMC6230893</ArticleId><ArticleId IdType="pubmed">29897822</ArticleId></ArticleIdList></Reference><Reference><Citation>Guthold R, Stevens GA, Riley LM, Bull FC. Worldwide trends in insufficient physical activity from 2001 to 2016: a pooled analysis of 358 population-based surveys with 1.9 million participants. Lancet Glob Heal. 2018;6(10):e1077&#x2013;e1086. doi: 10.1016/S2214-109X(18)30357-7..</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(18)30357-7.</ArticleId><ArticleId IdType="pubmed">30193830</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva PT de, Patias LD, Alvarez G da C, Kirsten VR, Colpo E, Moraes CMB de. Perfil de pacientes que buscam a cirurgia bari&#xe1;trica. Arq Bras Cir Dir. 2015;28(4):270&#x2013;273. doi: 10.1590/S0102-6720201500040013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/S0102-6720201500040013</ArticleId><ArticleId IdType="pmc">PMC4755181</ArticleId><ArticleId IdType="pubmed">26734799</ArticleId></ArticleIdList></Reference><Reference><Citation>Souza LPSE, Hermsdorff HHM, Miranda AES, Bressan J, Pimenta AM. Alcohol consumption and overweight in brazilian adults - cume project. Cienc e Saude Coletiva. 2021;26:4835&#x2013;4848. doi: 10.1590/1413-812320212611.3.20192019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/1413-812320212611.3.20192019</ArticleId><ArticleId IdType="pubmed">34787179</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres GG, Siqueira JH, Martinez OGE, Pereira TSS, Mel&#xe9;ndez JGV, Duncan BB. Consumption of alcoholic beverages and abdominal obesity cross-sectional analysis of ELSA-Brasil. Cien Saude Colet. 2022;27(2):737&#x2013;746. doi: 10.1590/1413-81232022272.02282021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/1413-81232022272.02282021</ArticleId><ArticleId IdType="pubmed">35137828</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssen F, Trias-Llim&#xf3;s S, Kunst AE. The combined impact of smoking, obesity and alcohol on life-expectancy trends in Europe. Int J Epidemiol. 2021;50(3):931&#x2013;941. doi: 10.1093/ije/dyaa273.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyaa273</ArticleId><ArticleId IdType="pmc">PMC8271206</ArticleId><ArticleId IdType="pubmed">33432332</ArticleId></ArticleIdList></Reference><Reference><Citation>King WC, Chen JY, Mitchell JE, Kalarchian MA, Steffen KJ, Engel SG. Prevalence of alcohol use disorders before and after bariatric surgery. JAMA. 2012;307(23):2516&#x2013;2525. doi: 10.1001/jama.2012.6147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2012.6147</ArticleId><ArticleId IdType="pmc">PMC3682834</ArticleId><ArticleId IdType="pubmed">22710289</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuttall FQ. Body Mass Index. Nutr Today. 2015;50(3):117&#x2013;128. doi: 10.1097/NT.0000000000000092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NT.0000000000000092</ArticleId><ArticleId IdType="pmc">PMC4890841</ArticleId><ArticleId IdType="pubmed">27340299</ArticleId></ArticleIdList></Reference><Reference><Citation>OPAS/OMS Wannmacher L Obesidade como fator de risco para morbidade e mortalidade evid&#xea;ncias sobre o manejo com medidas n&#xe3;o medicamentosas. OPAS/OMS - Represent Bras. 2016;1(7):1&#x2013;10.</Citation></Reference><Reference><Citation>Castro-Porras L, Rojas-Russell M, Aguilar-Rodr&#xed;guez MA, Giraldo-Rodr&#xed;guez L, Agudelo-Botero M. Sociodemographic and Clinical Factors Associated with Severe Obesity in Adults. Arch Med Res. 2022;53(2):196&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">34642068</ArticleId></ArticleIdList></Reference><Reference><Citation>Arantes AJA, Cangussu IV, Cangussu VV. Perfil epidemiol&#xf3;gico dos pacientes submetidos a cirurgia bari&#xe1;trica em hospital de ensino. HU Rev. 2022;45(1):1&#x2013;7. doi: 10.34019/1982-8047.2019.v45.16970.</Citation><ArticleIdList><ArticleId IdType="doi">10.34019/1982-8047.2019.v45.16970</ArticleId></ArticleIdList></Reference><Reference><Citation>Nora C, Morais T, Nora M, Coutinho J, do Carmo I, Monteiro MP. Gastrectomia vertical e bypass g&#xe1;strico no tratamento da s&#xed;ndrome metab&#xf3;lica. Rev Port Endocrinol Diabetes e Metab. 2016;11(1):23&#x2013;29. doi: 10.1016/j.rpedm.2015.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rpedm.2015.09.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Welbourn R, Hollyman M, Kinsman R, Dixon J, Liem R, Ottosson J. Bariatric surgery worldwide baseline demographic drescription and one-year outcomes from the fourth IFSO global registry report 2018. Obes Surg. 2019;29:782&#x2013;795. doi: 10.1007/s11695-018-3593-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11695-018-3593-1</ArticleId><ArticleId IdType="pubmed">30421326</ArticleId></ArticleIdList></Reference><Reference><Citation>Gr&#xf6;nroos S, Helmi&#xf6; M, Juuti A, Tiusanen R, Hurme S, L&#xf6;yttyniemi E. Effect of Laparoscopic Sleeve Gastrectomy vs Roux-en-Y Gastric Bypass on Weight Loss and Quality of Life at 7 Years in Patients With Morbid Obesity. JAMA Surg. 2021;156(2):137&#x2013;146. doi: 10.1001/jamasurg.2020.5666.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamasurg.2020.5666</ArticleId><ArticleId IdType="pmc">PMC7726698</ArticleId><ArticleId IdType="pubmed">33295955</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleman KJ, Wellman R, Fitzpatrick SL, Conroy MB, Hlavin C, Lewis KH, et al. Comparative Safety and Effectiveness of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy for Weight Loss and Type 2 Diabetes Across Race and Ethnicity in the PCORnet Bariatric Study Cohort. JAMA Surg. 2022;157(10):897&#x2013;906. doi: 10.1001/jamasurg.2022.3714.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamasurg.2022.3714</ArticleId><ArticleId IdType="pmc">PMC9434478</ArticleId><ArticleId IdType="pubmed">36044239</ArticleId></ArticleIdList></Reference><Reference><Citation>Arterburn D, Wellman R, Emiliano A, Smith SR, Odegaard AO, Murali S at al. Comparative Effectiveness and Safety of Bariatric Procedures for Weight Loss. Ann Intern Med. 2018;169(11):741&#x2013;750. doi: 10.7326/M17-2786.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M17-2786</ArticleId><ArticleId IdType="pmc">PMC6652193</ArticleId><ArticleId IdType="pubmed">30383139</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Kong X. Diabetes remission and relapse after metabolic surgery. J Diabetes Investig. 2018;9(6):1237&#x2013;1238. doi: 10.1111/jdi.12871.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdi.12871</ArticleId><ArticleId IdType="pmc">PMC6215947</ArticleId><ArticleId IdType="pubmed">29870156</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis KH, Arterburn DE, Zhang F, Callaway K, Wallace J, Fernandez A. Comparative Effectiveness of Vertical Sleeve Gastrectomy vs Roux en Y Gastric Bypass for Diabetes Treatment: A Claims-Based Cohort Study. Ann Surg. 2021;273(5):940&#x2013;948. doi: 10.1097/SLA.0000000000003391.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0000000000003391</ArticleId><ArticleId IdType="pmc">PMC7402414</ArticleId><ArticleId IdType="pubmed">31205064</ArticleId></ArticleIdList></Reference><Reference><Citation>McTigue KM, Wellman R, Nauman E, Anau J, Coley RY, Odor A. Comparing the 5-year diabetes outcomes of sleeve gastrectomy and gastric bypass the national patient-centered clinical research network (PCORNet) bariatric study. JAMA Surg. 2020;155(5):1&#x2013;12. doi: 10.1001/jamasurg.2020.0087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamasurg.2020.0087</ArticleId><ArticleId IdType="pmc">PMC7057171</ArticleId><ArticleId IdType="pubmed">32129809</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>